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INTRODUCTION  
INCIDENCE AND MORTALITY 
Worldwide, breast cancer is the most prevalent cancer as well as the most common 
female neoplasm accounting for 23% of all female cancers.1, 2 According to the world cancer 
report, more than one million cases occur worldwide each year, and 45% of these are in 
developing countries.1, 3 The incidence of breast cancer is increasing in most countries1, 4-7 but 
the outcome is now much better in the western world. The five-year survival rates are over 
70% in most of them1, 3 although racial differences still exist.3, 8, 9 This reduction in the 
morbidity and mortality rates of breast cancer in the developed countries has been due to 
increasing early detection by way of mass screening as well as improved targeted therapy.1, 3, 
8, 10  
In spite of this, breast cancer still remains the leading cause of cancer mortality in 
women worldwide. In 2002, the estimated number of deaths was about 411,000 (14% of 
female cancer deaths).1 Although the risk is still low in sub-Saharan Africa, the incidence of 
breast cancer is increasing rapidly in most African countries,2, 11  where breast cancer is more 
common in the urban population compared to the rural population.12 In Uganda it has doubled 
over three decades from 11/100,000 in 1965 to 22/100,000 in 1995 (Figure 1).13 It is now the 
second most common non-HIV related cancer14-16 affecting women in Uganda.13 
Unfortunately, the outcome is still very poor. Five-year survival rates have been found to be 
very low 29% and 34% for patient  with grade 3 and 2 tumors, respectively, in one study,17 
and similarly the overall 5-year survival rate was 38%18 and 56%19 in previous reports.   
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Figure 1: Trends in age-standardized incidence rate of breast cancer in Kampala, Uganda 
Adapted in part from Parkin et al. (2008)12 
 
 
ETIOLOGY AND RISK FACTORS 
The etiology of breast cancer is multi-factorial involving both genetic and 
environmental influences. Well known factors include genetic, dietary and reproductive 
factors plus related hormonal imbalances. Numerous studies have shown that most etiological 
and risk factors for breast cancer are related to the cumulative exposure of the breast to 
estrogens both endogenous and exogenous and include early menarche, nulliparity, late age at 
first pregnancy, late menopause (after 55 years) and hormonal replacement therapy. In 
addition, the other major influences on the risk of breast cancer include genetic susceptibility, 
body size and obesity, alcohol, physical activity, and possibly diet plus the western lifestyle.1-
3, 20  
Regarding genetic susceptibility, these factors contributes about 5-10% of breast 
carcinoma risk.21 The highest risk is due to germline mutations in the high penetrance breast 
cancer genes which include BRCA1, BRCA2, TP53, CDH1, PTEN and LKB1/STK11. Breast 
cancer susceptibility genes with low to moderate risk include CHEK2, TGF1, CASP8 and 
ATM.22 Of these, BRCA1 and BRCA2 germline mutations have been extensively studied.  
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Mutations of the other genes such as TP53, PTEN, STK11 CHEK2 and ATM result in a small 
proportion of breast cancer syndromes.23 Although family history has been reported to be a 
marker of risk of breast cancer in the African setting, the prevalence of BRCA1 mutations in 
African populations is not clearly known.24 
 
CLINICAL FEATURES  
Breast cancer is a highly heterogeneous disease with regards to morphology, hormonal 
receptor expression, invasive behavior, metastatic potential, as well as clinical behavior 
including response to treatment. Nevertheless, most primary invasive breast cancers are 
characterized by a palpable mass or lump, most frequently located in the upper outer quadrant 
and most often discovered by the patient.25 Other symptoms include nipple discharge, nipple 
lesions, skin edema plus redness and axillary lymphadenopathy. A small proportion will 
present with skin ulceration and skin retraction of the overlying skin or nipple.25  
However, the spectrum of breast cancer clinical presentation has been considerably 
changed by the introduction of mass screening by use of mammography. As a result of 
mammography screening, breast cancer tumor size and stage at presentation or detection have 
decreased.26-28 Whereas detection of non-invasive disease29 as well as impalpable breast 
lesions30 is more frequent. This has major implications on the management of breast cancer as 
well as on screening programs because of false positive cases and the lead time bias effects. 
Further, some racial differences in tumor size at presentation have been reported.31     
Regarding clinical presentation in African populations, it has been noted that African 
and African-American patients with breast cancer present in the late stages of the disease.12, 19, 
32-34 In Uganda, a recent retrospective study of medical records of breast cancer presenting at 
the national referral hospital revealed that a majority (77%) of patients presented in the late 
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stage according to the AJCC staging.35 Stage III was the peak stage at presentation with 51% 
of all patients, whereas 26% of patients had metastatic disease at presentation (Figure 2).19        
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Figure 2:  Stage at presentation of breast cancer patients presenting at the national referral 
hospital from 1996-2000. Adapted in part from Gakwaya et al. (2008)19  
 
 
TUMOR BIOLOGY  
The complex processes that characterize the development and progression of 
malignant tumors, the hallmarks of cancer, have been well described. They include self-
sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of apoptosis, 
unlimited replicative potential, sustained angiogenesis and tissue invasion and metastasis 
(Figure 3)36 plus the ability of the cancer to escape the immune response through several 
complex processes and events.37, 38   
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Further, the identification of cancer stem cells in breast cancer has led to more 
elucidation about evolution and progression of breast cancer.39 Also, research on morphologic 
and molecular features of hereditary breast cancer, especially in patients with germline 
mutations in BRCA1,23 a candidate stem cell regulator,40, 41 has increased our understanding of 
breast cancer biology. Gene expression profiling studies have extended our understanding of 
the molecular mechanisms involved in tumorigenesis and progression of breast cancer. Basic 
research on genes involved in signaling pathways modulating proliferation, apoptosis, 
survival, angiogenesis, invasion, metastasis and drug resistance have provided more answers 
to the heterogeneity of breast cancer. There is increasing evidence that this heterogeneity 
finds its source in genetic variability.42-45 
 
 
Figure 3: Hallmarks of cancer (Adapted from Hanahan and Weinberg, 2000).36 Loss of 
normal growth control as a hallmark of cancer which encompasses four (self-sufficiency in 
growth signals, insensitive to antigrowth signals, sustained proliferation and evasion of 
apoptosis) of the six hallmarks of cancer as defined by Hanahan and Weinberg (2000)36 
involve control over the cell cycle. 
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Cell cycle regulators and proliferation 
The cell cycle is a highly organized and complex process comprised of a series of 
tightly controlled events that drive the replication of DNA and ensures correct cell division. 
Cells are normally in the resting phase G0, and after appropriate stimuli they enter the 
proliferative phases of the cell cycle which is made of four phases; G1, S, G2 and M phase 
(Figure 4).  
 
Figure 4: The stages of the cell cycle indicating site of activity of regulatory CDK/cyclin 
complexes.46  
 
In the G1 phase, the cell is in a preparation for the S phase, in which DNA synthesis occurs 
followed by a second gap phase (G2) in preparation for the phase M in which the cell 
undergoes mitosis to generate two diploid G0 cells which may reenter the cell cycle or persist 
in the resting phase.47, 48 Cells are stimulated to divide in response to numerous external 
signals, including growth factors, hormones and cellular adhesion.47-49 During the G1 phase of 
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the cell cycle, cells are responsive to the external stimuli and are dependent on them until they 
reach the restriction point (R). This is a point of no return beyond which the cell is committed 
to enter the cell cycle and thereafter the process becomes autonomous.49  
The transition through the cell cycle phases is mediated by sequential assembly and 
activation of a family of serine/threonine proteins, the cyclin dependent kinases (CDK; 
CDK1, CDK2, CDK4, CDK6 and CDK7) and the CDK inhibitors (CKI; INK4 family: p15, 
p16, p18, p19; Cip/Kip family: p21, p27). The CKI are regulated by both internal and external 
signals such as the TP53 tumor suppressor gene and Transforming Growth Factor  (TGF-). 
The cell cycle has several check-points48 (Figure 5) to ensure an orderly sequence of events in 
the cell cycle as well as complete and accurate replication of the cell before division.48 Of 
these, the DNA damage check points (G1/S and G2/M) are well elucidated. Although it 
appears that oncogenic defects may target any major check-point, the most frequently  
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Figure 5: Check-points of the cell cycle. Adapted in part from Gillet et al. (1998).48   
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involved is the G1/S transition, and it encompasses many of the important cell cycle events 
that may be specifically altered in breast cancer including actions of the oncogenes (such as 
cyclin D1 and cyclin E) and tumor suppressors  (such as p27).  
 Control of cell proliferation in the normal mammary gland is steroid hormone 
dependent, and it involves complex interactions with other hormones, growth factors and 
cytokines as well as three proto-oncogenes (c-myc, cyclin D1 and cyclin E1). Proliferation is 
essential for tissue turnover but it exposes the cell to the occurrence of DNA damage.50 Cell 
proliferation plays an important role in the clinical behavior of breast carcinoma51 and it is a 
significant prognostic factor in breast cancer.52 Tissue homeostasis results from the balance 
between cell proliferation, differentiation and death in the form of apoptosis. An imbalance 
between cell proliferation and apoptosis contributes to tumorigenesis and tumor progression.  
 
Genetic factors  
Cancer is considered to be a genetic disease caused by genomic instability at the 
chromosomal or DNA level, and breast cancer has all the hallmarks of a multistep genetic 
disease.  Studies have shown that the development of human breast cancer is based on the 
accumulation of various genetic alterations,44 and almost every chromosome presents at least 
one site involved in cancer-related genetic alterations (chromosomal losses, DNA 
amplifications, mutations or altered DNA methylation patterns).45 The multistep process in 
breast cancer is driven by both inherited and acquired genetic alterations which result in 
changed expression of mRNA and various proteins.44 These abnormalities may be categorized 
into two; loss-of-function defects of tumor suppressor genes that have been inactivated by 
DNA mutation and unmasked by deletion or allelic loss, and gain-of-function genetic events 
that activate oncogenes.44 Several genetic alterations have been identified;36, 44, 53 somatic and 
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germline mutations have been described in tumor suppressor genes whereas oncogenes have 
been found to be activated.   
 
Tumor suppressor genes   
Several tumor suppressor genes have been implicated in breast carcinogenesis; 
mutations in genes such as BRCA1, BRCA2, TP53, PTEN or ATM or epigenetic functional 
inactivation of genes such as SYK and NESI play important early roles in formation of some 
breast cancers.54 Of particular significance are the germline mutations in the BRCA1/BRCA2 
genes and somatic alterations in the TP53 gene. Other genes of interest include the 
retinoblastoma gene (pRb), p16, NM23 and MASPIN.55  
   
BRCA1 and BRCA2 genes 
Studies have indicated that BRCA1 and BRCA2 are tumor suppressor genes which are 
essential for cellular development and are involved in repair of double-stranded breaks (DSB) 
and the maintenance of genome integrity as well as cell cycle control.56-59 BRCA1 has also 
been suggested to represent a stem cell regulator.40, 41 Mutations in these genes contribute to 
about 25-30% of hereditary breast cancer among young patients. In addition, it has been 
suggested that hypermethylation of BRCA1 and BRCA1 with inactivation may have a 
potential role in the carcinogenesis and aggressive phenotype of sporadic breast cancer.60-64   
Further, breast carcinomas occurring in women with BRCA1 mutations are more likely 
to occur at an earlier age and are frequently high grade, aneuploid, estrogen receptor (ER) and 
progesterone receptor (PR)  negative, p53 positive, have abundant lymphocyte infiltration and 
pushing margins.21, 22 They have also been shown to be associated with the basal-like 
phenotype,65 and are enriched with CD44+/CD24 stem cells.66 Decreased BRCA1 
expression has been associated with acquisition of metastatic capacity, the solid-tubular 
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phenotype, poor tubular formation, high tumor grade and overexpression of HER2 in sporadic 
tumors.61, 63, 64, 67  
   
TP53 gene   
The TP53 gene is the most frequently mutated gene in breast cancer and other human 
cancers.68 About 25% of breast cancers have somatic TP53 mutations,2 and 30-50% of breast 
tumors have overexpression of p53 protein.42 p53 is a nuclear transcription factor that is 
involved in control of gene transcription in the cell cycle (check-points)  and promotes 
chromosomal stability maintaining the integrity of the genome. It regulates cell proliferation 
and apoptosis by preventing replication of damaged DNA and division of genetically altered 
cells.69 p53 protein binds to damaged DNA and regulates transcription of a number of genes. 
Some of these genes, such as GADD45, p21 and MDM2, are transcriptionally activated by 
p53 whereas genes such as c-myc and c-fos are repressed by p53.70 The transcriptional 
activation of p21 during the G1 phase leads to cell cycle arrest and prevents cells with 
damaged DNA from entering the cell cycle phases of DNA synthesis and replication.70 In 
addition, the p53 gene transcriptionally activates bax, a pro-apoptotic gene and down 
regulates transcription of bcl-2 which is a powerful antiapoptotic proto-oncogene.70 
Consequently, inducing apoptosis through the bcl-2/bax pathway in susceptible cells in which 
the damage is beyond repair thereby protects the tissue against transmission of DNA 
abnormalities.50, 71-73 
Mutations in p53 adversely affect its ability to bind regulatory DNA sequences of 
these genes and thus to inhibit their transcriptional regulation resulting into a cascade of 
downstream effects.70, 73 Mutation of the p53 gene increases the risk of developing breast 
cancer and affects the biology of cancer cells and their response to therapy.70, 73 Mutations are 
more common in ductal carcinomas than in lobular carcinomas and are commonly associated 
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with BRCA1 and BRCA2 germline mutations.55 Also, TP53 mutations have been associated 
with more aggressive disease.74, 75 
 
Oncogenes  
Oncogenes refer to those genes whose alterations cause gain-of-function effects that 
lead to activation and can contribute to the development of cancer.76 Activation of oncogenes 
can occur through various ways; gene amplification, point mutation and chromosomal 
translocation.76 Oncogenes may also act cooperatively with other genetic or epigenetic 
changes.76 Numerous oncogenes have been characterized in human cancers but only few 
oncogenes are crucial in the development of breast cancer.44, 76 Amplification and 
overexpression of these oncogene and oncogene products are the major mechanisms through 
which they contribute to carcinogenesis.76  
In breast cancer, oncogene amplification is a common mechanism,44 and is an 
important mechanism for oncogene overexpression.77 The HER2, EGFR, c-myc, CCNDI, 
FGFR1, ESR1 and MDM2 are among the frequently amplified oncogenes. Coamplifications 
(HER2/c-myc or CCND1/FGFR1) have also been reported.45, 77   
 
HER2/neu gene 
The HER2/neu proto-oncogene is amplified in 15-30% of breast cancer.78 HER2 (also 
known as neu, c-erbB-2 or human epidermal growth factor 2) is a transmembrane protein with 
tyrosine kinase activity. HER2 has been implicated in breast carcinogenesis and plays an 
important role in development and progression of cancer.78 HER2 overexpression has been 
reported in 10-44% of human breast cancers.79-81 Overexpression in breast carcinoma occurs 
through either amplification of the gene or mRNA overexpression. This results in increased 
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cell proliferation, inhibition of apoptosis, and angiogenesis leading to poor prognosis in breast 
cancer.78, 82-85  
 
EGFR gene 
EGFR is another member of the tyrosine kinase family of receptors which are 
transmembrane proteins regulating major cellular events such as cell proliferation, 
differentiation, apoptosis, adhesion and cell migration.86-89 Several studies have established 
that EGFR gene acts as a cellular oncogene. EGFR gene amplification has been identified in 
0.8-14% of breast cancers.77, 90, 91 Epidermal growth factor influences the proliferation and 
differentiation of a wide variety of cancer cells, and plays a role in the pathogenesis of breast 
cancer.92, 93 In addition, it influences cell proliferation and a number of other processes in 
tumor progression such as cell survival, cell adhesion, cell motility, angiogenesis and tissue 
invasion.92 EGFR expression has been reported in about 45% (range 14-91%) of all breast 
cancers.94-96 
Amplification of EGFR in breast cancer indicates a more aggressive tumor behavior 
and a poor patient outcome.91, 97-100 Similarly, EGFR expression in breast cancers has been 
associated with features of poor prognosis including high tumor grade, elevated growth 
fraction, ER negativity and poor response to endocrine therapy and reduced survival.96, 101-104 
 
C-myc gene  
C-myc amplification is relatively common (8-37%) in breast cancer and may provide 
independent prognostic information.105 It encodes for a helix-loop/leucine zipper protein and 
myc responsive genes include those whose protein products regulate cell proliferation and 
apoptosis.105 The HER2/c-myc coamplified tumors have worse prognosis than tumors with 
only one of these amplified.45, 77 
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CCNDI gene  
The CCNDI gene located on chromosome 11q3 and coding for the G1-cyclin protein 
(cyclin D1) involved in regulation of the cell cycle47 has been found amplified in 10-27% of 
breast cancers.77 CCNDI amplifications are associated with ER and PR positivity, but studies 
on prognostic significance are still controversial.    
  
MDM2 gene 
The MDM2 gene protein product down regulates the TP53 tumor suppressor gene and 
is amplified in 4-7.7% of breast cancers and has been associated with poor prognosis in some 
studies.45, 77     
  
DNA ploidy  
DNA aneuploidy is a manifestation of chromosomal instability which is recognized as 
an early feature of malignant transformation and found to be an indicator of prognosis in 
breast cancer.106 The mechanisms responsible for the frequent instability of genomes of breast 
cancer cells have been poorly understood although recent functional findings on oncogene 
and tumor suppressor genes have provided more information about this matter.107 Studies 
have suggested that the DNA content of breast cancer cells reflects biologic properties 
associated with malignant behavior of the tumors.106, 108, 109   
    
Steroid receptors  
Ovarian steroid hormones estrogen and progesterone are necessary for normal 
mammary development and growth. The estrogen (ER) and progesterone receptors (PR) 
belong to the steroid hormone receptor family of inducible transcription factors that play a 
role in the development and progression of breast cancer.110-112 Studies have shown that 
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estrogen directly increases the growth of breast cancer cells in culture by increasing the 
number of cells entering the cell cycle (Figure 4). ER directly regulates several key G1 phase 
cell-cycle regulators (such as cyclin D1, Myc, cyclin E-CDK2 complex, CDK4 and CDK 
inhibitors) and those required for S phase entry.113-115 In addition, studies have suggested that 
PR induce cell cycle progression via activation of mitogen activated protein kinases in breast 
cancer cell lines.116 Steroid hormone receptors are directly involved in the development, 
progression and therapeutic responsiveness of breast cancer.   
ER is expressed in about 50-95% of breast carcinomas, while PR is expressed in 60% 
to 70% of the cases.117, 118  However, previous independent studies have shown a low 
prevalence of ER (23-33%) in women of African and African-American populations,32, 119-122 
although some studies reported higher frequencies (64-65%).123, 124 ER/PR positive tumors are 
more common in postmenopausal women and are more likely to be diploid, well 
differentiated, to have lower proliferative rates, and to be less aggressive than the receptor 
negative tumors.42  
Furthermore, estrogens in mammary epithelial cells and ER positive breast cancer cell 
lines have been shown to regulate,125 the expression of bcl-2, a powerful antiapoptotic proto-
oncogene.  
 
Apoptosis  
Apoptosis is a highly complex and tightly regulated process of cell death which 
deprives the proliferating cellular pool and allows the elimination of genetically damaged 
cells after their division. It is also a cellular protective mechanism against malignant 
transformation. Apoptosis regulation is ensured by various genes often associated with breast 
carcinogenesis, mostly pro-apoptotic (c-myc, p53 and ras) and rarely antiapoptotic (bcl-2). 
The bcl-2 gene was the first antiapoptotic gene to be described and is able to antagonize 
  24
apoptosis induced by several stimuli. Bcl-2 is one of the important regulators of apoptosis,126 
and it delays the induction of apoptosis in mammary glands.126, 127 The expression of the bcl-2 
gene is regulated by estrogens125 as well as down regulated by p53 in breast cancer cell 
lines.128 Several independent studies have shown that Bcl-2 overexpression in breast cancer 
correlates with biologic features of a differentiated phenotype (low proliferative rate, high 
levels of steroid receptor, weak or absent p53 expression and absence of HER2 expression).129 
The ability of tumor cells to evade apoptosis, as a hallmark of cancer,36 leads to 
continued proliferation of tumor cells and ultimate tumor expansion. Thus, dysregulation of 
apoptosis plays an important role in the pathogenesis and progression of breast cancer. The 
development and continued growth of cancers involve an interaction between cell 
proliferation and apoptosis.130-133 It has been shown that apoptosis is increased in invasive 
breast cancer134 and is positively correlated with Ki-67 expression.135 Breast tumors with 
increased apoptosis are more likely to be of high histologic grade and to be ER negative. 
Further, studies have shown that the rate of tumor growth depends in part on the excess of 
proliferation over apoptosis,130-133 and partly on angiogenesis.136   
 
Angiogenesis  
In 1971, Judah Folkman suggested that the growth and spread of malignant tumors 
were dependent on the process of angiogenesis, and that tumors could be treated by attacking 
their blood supply.136-139 Tumor-associated angiogenesis is now considered one of the key 
elements which contribute to tumorigenesis.140-143 Sustained angiogenesis, another hallmark 
of cancer,36 is a tumor micro-environmental process that is necessary for tumor cell survival, 
tumor growth, invasiveness, progression and development of metastasis, and beyond a critical 
volume a tumor can not expand further in absence of neovascularization.139, 142, 144-146 
Angiogenesis is a complex multi-step process, consisting of coordinated, sequential and 
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interdependent steps leading to formation of new blood vessels from pre-existing vascular 
networks.146, 147 It is a highly restricted process in normal human adult tissues, and in order to 
initiate it, a tumor must switch to the angiogenic phenotype. This occurs early in tumor 
development and limits or determines the rate of tumor progression.139, 141, 142, 146-148  The 
angiogenic switch is induced by the secretion of specific endothelial cell growth factors like 
VEGF (vascular endothelial growth factor) produced by the tumor cells plus other non-
malignant host cells recruited by the tumor.142, 146  
 
Vascular Endothelial Growth Factor   
The angiogenic switch of a tumor is related to a balance between positive and negative 
regulators (Figure 6). Several pro-angiogenic factors have been identified, and the vascular 
endothelial growth factor (VEGF) family plays a key role in this process as the major 
mediator of breast cancer angiogenesis.139, 141, 146, 149 VEGF is the most active, specific and 
potent mitogen for vascular endothelium among the endothelial cell growth factors,146, 150, 151 
and is a potent inducer of angiogenesis.139, 141, 149, 150, 152 It is secreted in response to 
environmental stimuli like hypoxia which is the main stimuli, certain cytokines and 
estradiol.146, 149 It plays crucial roles in cancer biology including endothelial cell proliferation 
and migration, promotion of tumor angiogenesis and metastasis.152, 153 Studies in breast cell 
lines showed that down regulation of the VEGF gene expression inhibited breast cancer cell-
induced angiogenesis and suppressed breast tumor metastasis in mice.154  
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Figure 6: The levels of the angiogenic inhibitors and activators factors control the 
angiogenic switch as well as the angiogenic activity of a tumors including breast cancer. 
Adapted from Hanahan (1996).141 
 
Furthermore, in vitro studies have shown that angiogenesis is also related to other 
molecular mechanisms involved in tumor growth and metastasis. Certain oncogenes such as 
HER2 signaling pathways promote angiogenesis by up-regulating cancer-cell production of 
angiogenic factor like VEGF.155, 156 In contrast, the p53 transcription factor has been reported 
to have a role in suppressing angiogenesis through enhancing the expression of 
Thrombospondin-1, an angiogenic inhibitor,157 as well as down regulating VEGF 
expression158 (Figure 6). p53 contributes to the angiogenic switch during tumorigenesis. It 
inhibits Hypoxia-inducible factor-1 (HIF-1) activity by targeting the HIF-1 for ubiquitination 
and proteasomal degradation.159 Thus, loss of p53 function leads to an amplification of normal 
HIF-1-dependent response to hypoxia,159 which is a key signal for induction of 
angiogenesis.160 Indeed, hypoxia is one of the most potent inducers of VEGF mRNA 
synthesis, a function achieved through inducing HIF-1.  
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Studies have shown that tumor growth, invasion and metastasis of breast carcinoma 
depend partly on angiogenesis.136, 154 Thus increased tumor angiogenesis has been associated 
with increased incidence of metastasis.161, 162  
 
  Invasion and metastasis  
Most deaths from cancer result from progressive growth of metastases that are 
resistant to conventional therapies, and in a significant number of patients metastases occur 
before diagnosis of the primary tumor.154 Tissue invasion and metastasis are exceedingly 
complex processes whose mechanisms are closely related but are poorly understood and are 
some of the acquired capabilities of cancer.36 The existence of an invading cancer does not 
necessarily imply metastasis, but invasive growth is a prerequisite for metastasis. Cancer cell 
invasion involves the breaching of tissue barriers by the cancer cells, and subsequent 
infiltration of these cells throughout the surrounding tissue.163 Several gene families are 
involved in this process. Acquired genetic alterations conferring growth advantage to the cells 
in addition to loss of cell-cell adhesion or cell-matrix adhesion and matrix remodeling all 
interplay to confer a migratory plasticity to the cancer cells.163, 164 Studies have indicated that 
the motility machinery of the cells is extremely important; and acquisition of a motile 
phenotype is essential for the tumor cells to become invasive.164, 165 Tumor cell motility is the 
hallmark of invasion and an essential step in metastasis, and evidence shows that tumor 
microenvironment might initiate the expression of genes that induce cell motility, invasion 
and metastasis.165-168     
Single epithelial cells can migrate through two predominant mechanisms.169 The 
mesenchymal migration which requires an epithelial-mesenchymal transition (EMT) is the 
predominant mechanism and requires matrix degrading enzymes. The second type, the 
amoeboid migration, enables cells to squeeze their way through the matrix without need for 
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the proteases and requires a mesenchymal-amoeboid transition (MAT). 164, 169, 170 This 
migratory method has implications for the treatment of breast cancer since it is used as a 
compensatory mechanism when the predominant one has been blocked.164, 170 Further, factors 
from the tumor microenvironment such as cytokines, growth factors, proteases and angiogenic 
factors secreted from multiple cell types plays a major role in determining the potential 
invasion and later metastasis in cancer.164 
Cell adhesion molecules play major roles in the invasion-metastasis cascade. Whereas 
activation of integrin v3 initiates calcium-dependent signaling pathway leading to increased 
cell motility and proteolysis,171 loss of E-cadherin expression facilitates tumor cell 
detachment enabling invasion and metastases.172 During tumor progression E-cadherin can be 
functionally inactivated or silenced by different mechanisms and loss of E-cadherin 
expression and/transcriptional repression of its mRNA are hallmarks of epithelial-
mesenchymal transition (EMT).173  
 
Epithelial-mesenchymal transition (EMT) 
By this process, polarized epithelial cells are converted into motile mesenchymal cells. 
The initial step of metastasis is epithelial-mesenchymal transition (EMT) which involves 
disruption of the adhesive interactions with surrounding cells and the acquisition of a motile 
phenotype. EMT is characterized by loss of polarity and down regulation of epithelial 
proteins, mostly E-cadherin, but also occludin, claudins, cytokeratins or catenin proteins in 
addition to inducing mesenchymal proteins like N-cadherin, vimentin and others.174 Multiple 
signaling pathways and effectors induce or contribute to the EMT and the key players include 
Receptor Tyrosine Kinases, the Transforming Growth Factor  superfamily, NF-B, WNT 
signaling, Notch signaling and Hedgehog signaling.173, 174 In addition, the EMT transcriptome 
program is controlled by several transcription factors outlined in Table 1.   
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Transcription factor  
Snail family  
     SNAI1 (Snail) 
     SNAI2 (Slug) 
ZEB family 
     SIP1/ZEB-2 
     EF-1/ZEB-1 
TWIST1 
TWIST2 
E12/E47 (E2A gene product) 
FOXC2 
Goosecoid  
 
Table 1: Transcription factors involved in the epithelial-mesenchymal transition.173-175   
 
The current model proposes that EMT is a two way process and EMT occurs at the 
invasion front of tumors whereas mesenchymal-epithelial transition (MET) occur at the 
secondary site (Figure 7).    
 
 
Figure 7: A reversible EMT model in tumor metastasis, with deregulation of cell 
proliferation and eventual acquisition of a motile phenotype; tumor cells breach the 
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basement membrane and enter the blood or lymphatic vessels. At the distant organ, the 
cancer cells exit the vessels and undergo a reverse mesenchymal-epithelial transition 
(MET) and regain their ability to proliferate. Adapted from Thiery et al.(2002)176  
 
EMT can promote metastasis in several ways and some of the EMT mediators also 
inhibit apoptosis (snail and twist families) which promotes tumor growth and expansion and 
mediate tumor immunosuppression (snail) potentially facilitating metastasis.174  
Metastasis is a complex process including primary tumor growth, local invasion 
through basement membrane and extracellular matrix, angiogenesis and lymphangiogenesis, 
dissemination to lymphatic and/or blood circulation, transport to distant organs and 
colonization at the secondary site.154 Recent evidence indicates that metastatic capacity is an 
early and inherent feature of breast tumors and not a late event. In breast cancer, metastases 
occur most commonly in the bone, lung and liver (Figure 8). Other relatively frequent sites 
include adrenal glands, pleura, gastrointestinal tract, brain and the peritoneum.177 Studies have 
shown that gene expression signatures can predict the likelihood178 of distant metastases with 
90% accuracy as well as the site179 of breast cancer metastases.  
In addition, gene expression studies178 identified a poor-prognosis signature which 
included genes involved in the cell cycle, signal transduction, angiogenesis, invasion and 
metastasis. These also included genes almost exclusively expressed by stromal cells such as 
MMP1 and MMP9 which are required for extracellular matrix (ECM) degradation and tumor 
invasion.180, 181  
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Figure 8: Common metastasis sites of breast cancer as seen at autopsy. Adapted 
from Weigelt, (2005).182 
 
  
The integrated model of breast cancer metastasis  
Further, gene expression profiles have demonstrated that the tumor microenvironment 
plays a significant role in tumorigenesis.166 Current evidence shows that tumor 
microenvironment initiates the expression of genes that induce cell motility, invasion and 
metastasis. Many of the EMT-inducing pathways play prominent roles in development and 
stem cell self-renewal.174 There is rapidly accumulating evidence which suggest that a link 
exists between stem cells and EMT.174 Mani et al. (2008) demonstrated that EMT induced by 
twist or snail endows breast epithelial cells with stem cell-like properties.183 Conversely, 
normal and neoplastic stem cells isolated from breast tissues show several features of EMT, 
and several signaling pathways that mediate stem cell self-renewal also induce EMT.174 
Further, it has been proposed that the biological and molecular heterogeneity184 as well as the 
risk of distant metastasis185, 186 corresponds with the amount of breast cancer stem cells (see 
  32
next section) in the tumor. Consequently, a new integrated model of breast cancer metastasis 
which is illustrated in Figure 9 has been proposed by Weigelt et al. (2005).182  
 
Figure 9: The integrated model of breast cancer metastasis, adapted from Weigelt et al. 
(2005).182 Oncogenic mutations occurring in the breast stem cells (red) and the 
differentiated progenitor cells (yellow) generate metastatic ‘poor prognosis’ (orange) and 
non-metastatic ‘good prognosis’ breast cancers (pink), respectively. In the metastatic 
tumors, under the influence of stromal fibroblasts, a small population of breast cancer stem 
cells has the ability to metastasize. There might be variants of cancer stem cells that differ 
in their tissue selectivity for metastasis, expressing additional tissue-specific profile (such as 
green; bone, purple; lung).   
 
Interestingly, studies in brain tumor cell lines have shown that cancer stem cells (CSC) 
contributes to the angiogenic drive in tumors by generating VEGF and other factors to induce 
angiogenesis.187, 188 The CSC-mediated VEGF production led to amplified endothelial cell 
migration and tube formation in vitro suggesting that cancer stem cells may be a crucial 
source of key proangiogenic factors in cancers.189 At the same time, tumor vasculature aids in 
maintaining CSC self-renewal and maintenance. Cancer stem cells depend on CSC 
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maintenance signals created by the vasculature similar to what has been observed in normal 
stem cells (Figure 10).187, 188  
 
 
Figure 10: CSC generate pro-angiogenic factors to stimulate angiogenesis while the tumor 
vasculature aids in maintaining CSC self renewal and maintenance. Adapted in part from 
Eyler and Rich (2008).188 
 
Cancer stem cells  
The term ‘cancer stem cell’ is an operational term defined as a cancer cell that has the 
ability to self-renew giving rise to another cancer stem cell as well as undergo differentiation 
to give rise to phenotypically diverse mixed populations of non-tumorigenic tumor cell 
populations in the tumor.190-192 The cancer stem cell hypothesis has fundamental implications 
for cancer biology and clinical management of patients.193, 194 It implies that breast cancers 
arise in mammary stem or progenitor cells through dysregulation of the normally tightly 
regulated process of self renewal.195 These “cancer stem cells” are thought to drive the growth 
and spread of tumors.190, 191 Therefore, failure to target them would set the stage for 
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recurrences and treatment failures.190, 191, 194 Studies in mouse models and established breast 
cancers have suggested that breast cancer behavior may be programmed in the precancer stem 
cells,196 and the amount of cancer stem cells within breast tumors may correspond to the 
biologic and molecular heterogeneity of the tumors184 as well as to risk of distant 
metastases.185, 186 Pece et al. (2010),184 characterized the transcription signature of human 
normal mammary stem cells (hNMSC signature) and by using markers of this signature 
isolated stem cells from both the normal gland and breast tumors. In xenografts, the hNMSC 
signature was able to predict the biologic and molecular features of breast cancers.184 The 
ability to identify these tumorigenic cancer cells has facilitated the elucidation of pathways 
that regulate their growth and survival,190, 191 and might lead to development of novel CSC-
targeted therapies197-199 which will eliminate breast CSCs.198, 199 
Importantly, exploration of cellular and molecular mechanism involved in the 
relationship between CSC and tumor angiogenesis that has been established in brain 
tumors187, 189 will provide opportunities for the development of novel CSC-targeted 
antiangiogenic therapies with advantage over currently available therapies.188, 197 
 
Stem cell markers  
The existence of stem cells in rodent mammary glands was first demonstrated by 
Kordon and Smith (1998).195, 200 Consequently, human mammary stem cells have been 
identified and purified based on their surface antigen expression.191, 201 Human breast cancers 
are reported to contain a subpopulation of cancer cells similar to epithelial stem cells, the 
“cancer stem cells”.185, 190, 192 Studies have shown that human breast cancers and cell lines 
contain a subpopulation of cells characterized by CD44+/CD24-/low/Lin- cell surface markers, 
and these cells have stem cell properties.190, 202 Breast cancer stem cells which expressed a 
combined CD44+/CD24/low/ALDH1+ phenotype showed an especially high tumorigenic 
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capacity.194 Also, in a recent study of 33 breast cell lines derived from human breast cancers 
and normal breast tissue, the results indicated that 23 of the cell lines contained functional 
cancer stem cells with metastatic capacity.203 In addition to increased aldehyde dehydrogenase 
1 (ALDH1) expression, BMI-1 expression has been reported as stem cell marker.194, 204, 205  
 
BMI-1 expression 
BMI-1 expression, a putative stem cell marker,204 is one of the several polycomb 
genes (PcG) which have been identified as oncogenes.206, 207 It was first identified as an 
oncogene that co-operates with c-myc in the generation of mouse pre B-cell lymphomas.208 It 
is a transcriptional repressor which acts as a key regulator of self-renewal activity in both 
normal and tumorigenic human mammary stem cells.209, 210 The PcG play a role in 
maintenance of cellular identity and contribute to regulation of the cell cycle by preserving 
gene silencing after cell division. Thus, dysregulation of this gene silencing machinery can 
lead to cancer,211-213 and BMI-1 has been implicated in breast cancer carcinogenesis, tumor 
progression and metastasis.206, 207, 214  
 
Aldehyde dehydrogenase 1  
ALDH1 is another stem cell marker which is considered to be an indicator of both 
normal and malignant stem and progenitor cells in the breast.194, 205 ALDH is a family of 
cytosolic isoenzymes responsible for oxidizing intracellular aldehydes, leading to oxidation of 
retinol to retinoic acid in early stem cell differentiation, which is important for proliferation, 
differentiation and survival.215-217 ALDH1 (also known as ALDH1A1) is the predominant 
ALDH isoform in mammals,217-220 and it is highly expressed in the hematopoietic progenitors 
and in intestinal crypt cells as well as in breast tumor cells.205, 221, 222 In breast cancer, ALDH1 
expression has been associated with poor clinical outcome, resistance to chemotherapy and 
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the basal-like phenotype of breast cancer.193, 194, 205 Also, in a recent study, in both in vitro and 
xenografts, the results showed that invasion and metastasis in inflammatory breast cancer are 
mediated by a CSC component that displays ALDH enzymatic activity,223 and 
ALDEFLUOR-positive cells were found to be responsible for mediating metastasis in a study 
involving 33 cell lines derived from breast tissues.203     
  
MOLECULAR PHENOTYPES OF BREAST CANCER 
Gene clustering analyses have indicated that breast cancer can be divided into two 
broad categories; ER+ and ER groups which can further be subdivided into additional 
biologically different and clinically significant subgroups. Thus, five different sets of intrinsic 
gene clusters were recognized (luminal A, luminal B, the HER2+ subtype, the basal-like and 
the normal breast-like category) with different prognosis in multiple independent studies.224-
228 Although gene expression profiling is the gold standard for molecular classification of 
breast cancer, its large scale clinical use or use in retrospective studies is limited by the strict 
tissue requirements (fresh and frozen tissue) and by issues of cost, complexity and technical 
feasibility.229, 230 Consequently, in an attempt to develop a molecular classification that is 
clinically significant, technically simple, reproducible, and readily available, investigators 
have proposed an immunohistochemical-based classification.229 These biomarkers can define 
the molecular subgroups in the routine and readily available formalin-fixed, paraffin 
embedded tissues by way of immunohistochemical staining. Although some of the proposed 
IHC markers have been validated using a 930-case tissue microarray,231, 232 there is, however, 
still no consensus on these definitions,233 and overlapping categories exist. By using the 
immunohistochemical classification, four similar major subgroups have emerged as well as 
the unclassified tumors (Figure 11) which encompass the normal breast-like class of breast 
cancer that is still poorly characterized immunohistochemically.233 Of these, the basal-like 
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breast cancer (also known as basal-like phenotype or basal-like subtype) and the HER2+ 
subtype are of particular interest since they have a poor prognosis.226 
 
 
 
Figure 11: The immunohistochemical subclassification of breast cancer (simplified)   
 
Basal-like subtype   
There is no consensus on how to define this subgroup. Basically, these tumors might 
be defined on the basis of expression of various basal markers. Alternatively, negativity for 
ER, HER2 and eventually PR might be added to obtain more composite basal-like profiles. 
According to the latter, basal-like breast carcinomas usually lack ER and HER2 and express 
genes characteristic of basal or myoepithelial cells such as basal cytokeratins (CK5, CK14, 
CK17) and other genes characteristic of basal-like cells of the breast.233-237 In addition to 
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structural roles, many of the basal-like gene products have been implicated in cellular 
proliferation, suppression of apoptosis, cell migration and invasion, all hallmarks of cancer.36, 
228, 233 Indeed, gene expression studies have further shown that a majority of basal-like tumors 
express the activated wound-response signature,238 which represents important processes 
likely to contribute to cancer invasion and metastasis such as matrix remodeling, cell motility 
and angiogenesis. 
Further, it has been suggested that different subtypes of breast cancer might originate 
from breast stem or progenitor cells at distinct stages of lineage differentiation, with basal-like 
tumors arising from the most-primitive ER-negative stem cells.239-241 Gene expression profile 
studies of basal-like tumors have suggested a less differentiated breast stem cell or progenitor 
cell of origin for these tumors241 and several gene products in the basal cluster are also 
expressed in stem cells of various tissue types.241, 242 Given the central role of BRCA1 in 
normal mammary development,243 Foulkes (2004)40 proposed that BRCA1 regulates 
differentiation of breast stem cells, and defects in the BRCA1 pathway might arrest further 
differentiation of these cells leading to cancer. Subsequent studies have provided some 
evidence that basal-like breast cancers originate in stem cells with maturation defects and 
genomic instability caused by BRCA1 mutations.41, 194 
The basal-like breast carcinomas contribute about 8-25% of all breast cancers as 
defined using gene expression or IHC surrogate criteria.233, 241, 244 They express basal markers 
such as basal cytokeratins in addition to other makers like EGFR, P-cadherin, p63 and c-
kit.231, 232, 236, 245-247 However, unexpectedly, basal-like tumors might also co-express luminal 
cytokeratins CK8 and CK18.241 The basal-like subgroup partially overlaps with the so called 
triple negative tumors defined as being ER/PR/HER2, as well as the BRCA1 associated 
breast cancers (Figure 12).233, 248 A majority (82%) of basal-like breast tumor were found to 
contain p53 mutations.226   
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Clinically, the basal-like tumors have been associated with younger age (< 40 years) 
and are more likely premenopausal African-American women in some studies.231, 249 Studies 
have shown than the basal-like subtype seems to differ by race and age, whereas other major 
subtypes do not seem to show a clear difference.229, 231, 249 Also, previous reports have 
indicated that the hormonal receptor negative tumors as well as the basal-like subtype are 
overrepresented in women from African population.120  
 
 
 
Figure 12: The interrelationships of the basal like (BP), the triple negative (TNBCs) and 
the BRCA1 associated breast carcinomas. Adapted from Diaz et al. (2007) 248  
 
Morphologically, a majority of basal-like breast cancers are usually of high histologic 
grade and invasive ductal carcinomas. The basal-like tumors are seen as sheets of cells with 
minimal tubule formation which are more likely to have a pushing non-infiltrative tumor 
border, higher degree of stromal lymphoplasmacytic infiltration and larger zones of 
geographic necrosis than the non basal-like tumors. These characteristics represent medullary 
features.250 Morphologic characteristics of basal-like breast cancers that have been confirmed 
in a number of independent studies, although not in all, are listed in Table 2, but however they 
may also be found in other grade 3 non basal-like tumors. The high proliferative rate of basal-
like tumors which has been reported in some reports248, 251 may explain their 
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overrepresentation among so called interval breast cancers.252 Further, Foulkes et al. (2004)253 
observed that glomeruloid microvascular proliferation (GMP), a histologic marker of an 
aggressive angiogenic phenotype in human cancer,254 was significantly more frequent in the 
basal-like subgroup of breast cancer. 
 
Table 2: Morphologic characteristics of basal like breast cancer233, 248, 250  
Characteristic  
     Pushing invasion border 
     Central scar or sclerosis 
     Geographic tumor necrosis  
     Marked cellular pleomorphism 
     High nuclear grade 
     High mitotic count (average 45 mitoses per 10 high power fields)  
     High nuclear-cytoplasmic ratio  
     Vesicular chromatin 
     Prominent nucleoli 
     Lack of tubule formation 
     Frequent apoptotic cells  
     Spindled tumor cells  
     Metaplastic features  such as squamous cell metaplasia 
     Scant stromal content  
      Exaggerated stromal lymphoplasmacytic response 
 
Interestingly, the basal-like subgroup is reported to have a specific pattern of 
metastatic spread with reduced lymphatic metastases and increased hematogenic spread to 
sites associated with poor prognosis.250, 255 They show relatively increased propensity for the 
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lungs and brain metastases whereas they have a decreased propensity for bone and liver 
metastases.250 Thus it has been proposed that basal-like breast cancer posses a distinct 
mechanism of metastatic spread.230  
Regarding the therapeutic implications of the molecular subtypes, a recent report has 
suggested that some chemotherapeutic agents might have different mechanisms of action in 
different subtype of breast cancer.256 The basal-like breast cancers are resistant to currently 
available therapeutic targets for breast cancer, although they may be responsive to EGFR 
targeted therapy.229, 257, 258 Also, studies have shown that ER negative tumors benefit twice as 
much from chemotherapy than the ER positive tumors. A number of studies,259-261 although 
not all,262 have indicated that basal-like tumors have a higher response rate to chemotherapy 
both as adjuvant and neoadjuvant regimens compared to the luminal subtype.   
The current challenge is to identify novel target molecules and pathways for the basal-
like subtype which is frequently triple negative. Some possible targets that have been 
proposed include EGFR and VEGF.258, 263 C-kit which is expressed in a high proportion of 
basal-like tumors might also be a suitable target.264 However, c-kit positive breast tumors 
have been shown to lack activating c-kit mutations which conveys sensitivity to imatinib, a c-
kit inhibitor.229, 233 The biologic similarities between BRCA1 associated and basal-like tumors 
have suggested that strategies like PARP inhibitors targeting DNA-repair defects of the 
BRCA1 pathway dysfunction in basal-like tumors might be effective.265, 266       
 
Other subtypes  
In general, the HER2+ subtype has been defined as ER/PR and HER2 positive 
tumors.229, 231, 233 The HER2+ tumors express high levels of genes located in the HER2 
amplicon including HER2 and the GATA4 transcription factor. They lack expression of ER 
and GATA3. Current literature shows that it contributes about 8-12% of the breast cancers.124, 
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231, 244, 267 This is an aggressive subtype which has been associated with high histologic grade 
and reduced survival.78 Fortunately, the clinical outcome of patients with HER2 positive 
tumors has been greatly improved by development of HER2 targeted therapy like trastuzumab 
which is now routine treatment for breast cancer. Thus, HER2 expression is a predictive 
factor currently in use.268  
Luminal tumors are ER positive tumors that express ER responsive genes and other 
genes that encode characteristic proteins of luminal epithelial cells such as PR, GATA3, BCL-
2 and the luminal cytokeratins 8 and 18.241 They contribute about 50-70% of breast cancers.229 
Luminal tumors are usually associated with increasing age, low histologic grade, they are less 
aggressive and have a good prognosis and will respond to hormonal therapy. The luminal A 
subtype is most frequent and has a better prognosis than luminal B tumors which are more 
frequently ER+/PR,229 and have a higher tumor cell proliferation. 
The normal breast-like subtype is also a predominantly ER negative group.241 It has  
relatively high expression of many genes known to be expressed by adipose tissue and other 
non epithelial cell types as well as strong expression of genes in the basal cluster but low 
expression of luminal epithelial genes.226, 229 However, some reports have suggested that it 
may potentially be due to normal tissue contamination.229, 269 This group is still poorly 
characterized, most IHC studies have not included this subtype because of its complex 
expression patterns which can not be summarized into a simple 5-marker panel.229, 270         
 
PROGNOSTIC AND PREDICTIVE FACTORS  
Currently, histopathologic evaluation of breast cancer includes a detailed description 
of morphologic patterns and biologic parameters of the tumor, including prognostic and 
predictive factors.271, 272 A prognostic marker might be related to molecular mechanisms 
involved in tumor growth, progression, invasion and metastasis and gives significant 
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information on clinical outcome for groups of patients. A predictive factor is a clinical, 
pathologic or biologic feature that is used to estimate the likelihood of response to a particular 
type of adjuvant therapy.42, 273 Hence, the use of prognostic and predictive factors has mainly 
three reasons,274 to identify patients: 
• who may not require adjuvant therapy after local surgery  
• whose prognosis is poor enough to warrant a more aggressive adjuvant therapy  
• whose tumors are more likely to be responsive or resistant to particular types of 
therapy  
Several potentially useful prognostic and predictive factors have been suggested and 
can broadly be categorized into clinico-pathologic factors and biologic factors including 
tumor biomarkers as shown in Table 3. The College of American Pathologists275 has 
categorized such factors into 3 groups. Category I, are factors with prognostic importance 
being useful in clinical management of patients; Category II includes factors that have been 
extensively studied, but whose importance remains to be validated in statistically robust 
studies; Category III includes all other markers not sufficiently studied to demonstrate their 
prognostic value.     
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Table 3: Useful and potential prognostic and predictive parameters in breast cancer.42 
Parameter 
Patient related factors  
    Age at diagnosis  
    Ethnicity/race     
Histopathologic features  
    Tumor  size  
    Tumor differentiation 
          Histologic type 
          Histologic grade  
    Lymph nodes status (stage)  
    Vascular invasion 
Cell cycle and  proliferation  
    Mitotic count/Mitotic index  
    Ki-67/MIB-1 
   DNA S-phase fraction (flow cytometry) 
    DNA/ploidy (flow cytometry)  
    Cyclin E    
Steroid Receptors 
    ER/PR   
Growth factors and receptors  
    HER2 
    EGFR 
Tumor suppressor genes 
    TP53 
Measures of invasiveness 
    Cathepsin D 
    Plasminogen activator inhibitor-1 (PAI-1) 
    Urokinase plasminogen activator (uPA)  
    Laminin receptors  
Angiogenesis  
    MVD 
    VEGF 
Multiparameter gene expression analysis  
    Oncotype DX assay 
    MammaPrint   
    Rotterdam signature  
    Breast Cancer Gene Expression ratio   
Composite  prognostic factors  
    Nottingham Prognostic Index 
    TNM and pTNM classification 
Others  
    Tumor necrosis 
    Stromal fibrosis /elastosis 
    Basal-like phenotype 
    Triple negativity 
    Stem cell markers 
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Clinical factors   
Age at diagnosis is one of the useful prognostic indicator in breast cancer.42 Several 
independent studies have shown that young breast cancer patients (35 years) have more 
aggressive biologic characteristics and poorer prognosis.276-278 Consequently, age (<35 years) 
is one of the parameters which was recommended by the St Gallen 2007 conference, used to 
determine the risk category of patients.279, 280 On the other hand, the older patients (>70 years) 
also exhibit poor survival or higher mortality due to other factors.278 Interestingly, breast 
cancer in African and African-American women is diagnosed about 10-15 years earlier than 
in women from Caucasians populations.281, 282   
Related to this, race and ethnicity is another patient-related factor that has been 
proposed as a prognostic marker although it is still a matter of debate, and numerous 
independent studies have shown that breast cancer in Africans and African-American has 
poorer prognosis than in Caucasians.33, 282-286 Indeed, compared with Caucasian women, 
African-American women, regardless of age presented with higher histologic grade for each 
stage of breast cancer and tumor size above 1 cm in a study by Henson et al in 2003.284    
 
Histopathologic factors  
Histologic grade is one of the most widely used prognostic factors. Using traditional 
morphologic features (tumor glands, nuclear pleomorphism and mitotic frequency), by careful 
examining of breast cancer specimens, can provide significant prognostic information 
required for therapeutic stratification. For accurate evaluation, good fixation and specimen 
preparation are very important in assessing these features. The traditional factors which are 
the most widely used prognostic markers and have the greatest value in clinical management 
of patients include; histologic type, histologic grade, tumor diameter, lymph node status, and 
vascular invasion,42, 278, 287, 288 as well as distance to resection margins.  
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 Assessment of tumor differentiation (histologic type, histologic grade) gives an 
indication of the underlying biology within a given tumor. The prognostic value of certain 
histologic types of invasive carcinoma has been well-established and may be grouped into 
four categories ranging from excellent to very poor prognosis.278, 288 However, in multivariate 
analysis, histologic grade is a more powerful prognostic factor than histologic type.  
Several studies have shown significant correlations between histologic grade and 
survival of breast cancer patients,271 although a significant concern has been the 
reproducibility of grading. Currently, two grading systems are widely used, the Nottingham 
method (modified Scarff-Bloom-Richardson) and the Fisher nuclear grading method. The 
Nottingham system with its more objective criteria has good to excellent reproducibility when 
used by experienced pathologists,289, 290 hence, it is the most widely used and is currently 
recommended. It evaluates glandular differentiation, nuclear pleomorphism and mitotic 
counts ultimately generating three tumor grades.42, 291  
Tumor diameter is one of the strongest prognostic indicators even after 20 years of 
follow-up.278 Consequently, it has become an important quality assurance measure for breast 
screening programs. However, for its prognostic correlation it should be assessed on 
pathologic specimens (pathologic tumor size), and the greatest diameter is considered as the 
final tumor size.288 
Multiple studies have shown that histologically determined axillary lymph node status 
is one of the strongest independent prognostic factors in breast cancer.42, 275, 291 However, 
there is still some debate about the use of axillary clearance or sentinel lymph node biopsy291 
although the latter is frequently used. At a recent St Gallen meeting (2009), the use of sentinel 
node biopsy was considered as standard care for patients with clinically negative axilla.292 
Nevertheless, it is generally recommended that, in order to obtain accurate histologic 
evaluation of lymph node stage, several blocks from each node submitted for examination 
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should be examined.275, 291, 293 The St Gallen conference 2005 identified nodal status including 
sentinel node status as the most important feature for defining risk category in patient with 
breast cancer which was reaffirmed in a subsequent meeting.280, 294 The absolute number of 
nodes involved is useful in determining the thresholds for treatment modalities in the same 
group of patients.292  
Closely related to lymph node status is vascular invasion. Presence of vascular 
invasion correlates closely with lymph node involvement, and it has been suggested as a 
surrogate for lymph node status in cases where nodes have not been removed for 
examination.291 Vascular invasion is a powerful predictor of local recurrence following 
surgery and a prognostic factor for reduced overall survival. It has been recommended that 
vascular invasion should be assessed in routinely processed tissue with extra care to avoid 
artifacts of retraction spaces.275, 291 Interobserver variability about the topographical patterns 
of vascular invasion still exists275 and is a matter of debate.      
Regarding the composite prognostic factors, the UICC TNM classification which 
evaluates the primary tumor size (T), regional lymph node status (N) and presence of distant 
metastasis (M) is commonly used for breast cancer patients at the time of diagnosis (Figure 
13). The tumor stage at the time of diagnosis is one of the strongest prognostic factors in 
breast cancer. The pTNM classification requires examination of the primary cancer with no 
gross tumor at the margins of resection and is similarly categorized as pT (corresponds to T 
category), pN and pM (corresponds to M category). The pN classification requires the 
resection and examination of at least the lower axillary (level 1) lymph nodes. However, 
sentinel nodes may be used, but even then the grading should be designated (sn) for sentinel 
node, for example pN1(sn).2       
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Figure 13: TNM classification. The TNM classification is an anatomically based system 
that records the primary and regional nodal extent of the tumor and the absence or 
presence of distant metastases. T category describes the primary tumor site, N category 
describes the regional lymph node involvement, and M category describes the presence or 
absence of distant metastases.295 
 
 
The Nottingham Prognostic Index (NPI), another composite parameter which includes 
nodal status, tumor diameter and histologic grade, is a strong prognostic assessment method, 
although inclusion of tumor biomarkers like ER status and HER2 expression to the NPI offers 
additional information about selection of patients for systemic adjuvant therapy.296   
In 2007, prognostic factors such as histologic tumor grade, lymph node status, 
peritumoral vascular invasion (PVI), pathologic tumor size and patients age in addition to 
biomarkers were the criteria used to determine the risk category of patients by the St Gallen’s 
conference.294 Addition of proliferation assessed either by Ki-67 or mitotic count to the 
pathologic factors was later used to determine the algorithm for threshold of treatment 
modalities by the recent St Gallen’ conference 2009.292    
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Tumor biomarkers and biologic factors  
Over the years, researchers have continued to identify and propose several biomarkers 
as putative prognostic and predictive factors in breast cancer (Table 3) that might help to 
better stratify patients to various treatment regimens as well as targeted therapies. These novel 
biomarkers reflect alterations in genes that regulate development and proliferation of 
tumors.42 However, three biomarkers (ER/PR and HER2 expression) have become standard 
measurements in the management of breast cancer patients. In addition, some factors have 
recently been recommended for clinical use.272, 297 The uPA and PAI-1 which should be 
measured by ELISA may be used to determine prognosis in node negative breast cancer,272 
although the St Gallen conference did not accept uPA/PAI-1 as a useful prognostic factor.292 
In addition, the Oncotype Dx multiparameter gene expression analysis may be used to predict 
the risk of recurrence in patients with ER positive breast cancer who are treated with 
tamoxifen272 if readily available.292       
Estrogen receptor status is a widely applied factor that is used to predict response to 
hormonal therapy in both early and metastatic disease.272, 297 Prediction of response can be 
refined further by combing ER and PR assays.271 Also, it has been suggested that absence of 
PR may indicate increased signaling of HER2 and may help clinicians decide between using 
aromatase inhibitor or tamoxifen.298 In addition, ER expression has been shown to predict the 
long-term outcome of hormonal therapy,278 and is associated with improved overall survival 
although its use as a prognostic factor is limited.42, 272, 299  
HER2 expression has been associated with poor prognosis in breast carcinoma78, 84 
including poor response to both chemotherapy and hormonal therapy.268 Studies have shown 
that HER2 status may be used to predict resistance to tamoxifen or cyclophosphamide-based 
therapy and enhanced response to anthracycline-based therapy in early breast cancer. 
However, its current clinical use is limited to predicting the response to HER2 targeted 
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therapy and selection of patients for treatment with trastuzumab.272, 297 Other utilities for 
HER2 status are still undergoing further evaluation.   
Gene expression studies have shown that proliferation is the most important 
component in many prognostic signatures.300 Cell proliferation plays a major role in the 
behavior of breast cancer, and increased proliferation correlates strongly with prognosis 
irrespective of the methodology used.51 Several methods of assessing proliferation have been 
studied (Table 3), but mitosis counting provides the most reproducible and independent 
prognostic information.51, 301 Currently, it is recommended by the College of American 
Pathologists,275 that assessment of cell proliferation should be performed routinely in 
evaluation of breast cancers, and mitotic figure counting might be sufficient enough for this 
purpose. It was found to be the most important prognostic component of the Nottingham 
grading system,51 and the mitotic activity index (MAI) was validated as the strongest 
independent and well reproducible prognosticator in lymph node negative patients.302 
Assessment of other proliferation markers such as Ki-67 is currently optional.275 
Ki-67 is a nuclear antigen that was identified by Gerdes et al. (1991),303 and is 
expressed only in the proliferative phases of the cell cycle G1, S, G2 and M but absent in G0. It 
can be used to stratify patients into good or poor prognostic groups.275, 304 However, results 
from different groups are still conflicting and therefore its use in routine clinical management 
of breast cancer is still undetermined.305 The Norwegian Breast Cancer Group has recently 
(February 2010) recommended its use in subgroups of breast cancer. The St Gallen 
conference in 2009 considered Ki-67-labelling index a useful factor that could be used to 
indicate the potential value of adding adjuvant chemotherapy in patients with receptor 
positive disease.292    
For the TP53 gene, mutation status and gene expression profiles have been suggested 
as powerful prognostic markers in breast cancer.272, 306, 307 In addition, p53 expression has 
  51
been associated with poor prognostic factors and poor survival,308, 309 and may be a prognostic 
marker in nodal negative breast cancer patients.42, 275, 310 In addition, it can help to identify 
patients likely to response to chemotherapy or radiotherapy,42, 275, 310 but its use as a 
prognostic or predictive factor is still controversial. Present data are insufficient to 
recommend clinical use of p53 in breast cancer patients. Moreover, the IHC detection of p53 
expression is variable and, does not detect all TP53 mutations. A consensus on how to assess 
the staining has not yet occurred.42, 272, 275 
EGFR expression has been reported as one of the biomarkers which may be a 
candidate for clinical application in the near future.94 Several independent studies have shown 
that EGFR expression in breast cancer is associated with features of aggressive tumors and 
poor response to tamoxifen.42, 311 Present data suggest that some patient groups with breast 
cancer could benefit from EGFR-targeted therapy.94, 258, 312 EGFR status might possibly have 
a predictive role for response to such therapy,313 although detection and interpretation of 
EGFR is controversial and still needs to be standardized.94, 311 Indeed, results from a trial in 
which patients were treated on the basis of EGFR expression are promising.94, 314 On the 
contrary, different studies have provided conflicting results concerning the prognostic and 
predictive significance of EGFR, and its routine value in clinical management of breast cancer 
patients is still undetermined.42, 311, 315   
Growth, invasion and metastasis of breast carcinoma depend on angiogenesis, and thus 
tumor-associated angiogenesis has attracted much attention and has been extensively studied 
as a possible prognostic or even predictive factor in breast cancer.271, 316, 317 Several 
independent studies, although not all, have proposed that tumor angiogenesis is an 
independent prognostic factor and is associated with the risk of distant metastases and poor 
survival.316, 318-320 However, the prognostic significance of angiogenesis remains somewhat 
controversial. This is mainly due to the variability in measurement of angiogenesis by 
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assessing the microvessel density (MVD) as a surrogate marker of the degree of 
angiogenesis.139, 275 The assessment of MVD within a selected tumor area (hot spot) is too 
variable to be clinically useful.317, 319, 321  
Another surrogate marker of angiogenesis with prognostic significance is VEGF 
expression, which was also found to correlate with MVD in some studies.318 VEGF has been 
reported as an independent marker of poor prognosis in some studies,42, 308, 322 and high 
expression of VEGF can identify a subgroup of patients who may benefit from selective anti-
angiogenic therapy.42, 153  However, the clinical use of VEGF is still undetermined.  
In addition to the above factors, other parameters which might become of clinical 
importance in breast cancer include but are not limited to the triple negative phenotype, the 
basal-like subtype and cancer stem cell markers.292, 294 The triple negative phenotype (TNP) is 
characterized by lack of ER/PR/HER2 and has recently been recognized as a group with 
therapeutic implications. It lacks targeted therapy whereas it is frequently resistant to standard 
chemotherapeutic regimens.248 Multiple studies have reported the poor prognosis associated 
with TNP,323 although the use of TNP as a prognostic factor is still not well studied.248 
Further, molecular predictive signatures will enable characterization of triple negative breast 
cancers better and design of optimal treatment modalities.324 Indeed, the recent St Gallen’s 
conference (2009)292 recommended the use of triple negativity as a parameter that can be used 
to select some patients for chemotherapy.      
Similarly, the basal-like phenotype which partially overlaps with the TNP and BRCA1 
associated breast cancer,65, 248 has a poor prognosis with clinical importance.248, 325 It is 
associated with the shortest relapse-free and overall survival,226, 230 although its use as a 
prognostic factor is still not well studied.305 It has been suggested that pathologists should 
routinely identify the BLP in breast cancer,325 and incorporate the specific morphological 
features associated with the basal-like tumors (Table 2) with standard biomarkers such as 
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ER/PR and HER2 which might aid clinicians in developing optimal therapeutic strategies for 
this group.248       
The presence of cancer stem cells might have prognostic and therapeutic implications 
in breast cancer.191, 193, 194 Studies in cell lines have indicated that cancer stem cells have a 
drug-resistant phenotype,326, 327 and express drug-resistance proteins such as ABCG2 (breast 
cancer resistance protein). In addition, breast cancer stem cells displayed resistance to both 
radiotherapy and tamoxifen treatment at clinically relevant doses.191, 328, 329 Further, it has 
been found that breast cancer stem cells metastasize to the bone marrow in early-stage breast 
cancer.330 Hence, it might be difficult to eradicate such drug-resistant stem-like cells from the 
bone marrow of patients using traditional chemotherapy only. The ability to identify cancer 
stem cells has facilitated the elucidation of pathways that regulate their growth and 
survival,190, 191 and has provided a deeper understanding of the natural evolution of cancer as 
well as clinical behavior and response to treatment.   
Studies in vitro and in xenografts have indicated that breast cancer stem cells display 
distinct molecular signatures; the 413-gene CSC signature203 and the hNMSC signature,184 
which might be potential prognostic parameters. The hNMSC signature could be used to 
predict biologic and molecular features of breast cancer.184 Stem cell markers like ALDH1 
expression have been associated with poor prognosis,193, 194 and studies have also suggested 
that levels of ALDH1 expression in primary breast cancer can be used to predict the response 
to chemotherapy.193, 222, 331 Also, in the inflammatory breast cancer ALDH1 expression was 
found to be an independent prognostic marker that can predict metastasis and poor patient 
outcome,223 whereas in pancreatic adenocarcinoma ALDH1 expression was associated with a 
worse survival.332 However, the clinical significance of breast cancer stem cells and stem cell 
markers is still undetermined.  
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DIAGNOSIS AND TREATMENT   
 Optimal breast cancer management requires a multidisciplinary or interdisciplinary 
team approach involving surgeons, oncologists, radiologists, pathologists, geneticists,333, 334 
and possibly psychosocial specialists. Accurate diagnosis is a necessary step in the 
management of breast cancer and ideally every patient should have a pathologic diagnosis of 
breast cancer before definitive treatment can be given.335 Accurate diagnosis confirms the 
presence or absence of breast cancer and thus, avoids unnecessary treatment in patients with 
benign conditions, and in addition provides prognostic and predictive features of the cancer, 
which help in planning treatment and counseling of the patient with breast cancer.335  
 A fundamental principle in evaluation of breast cancer patients is the triple-test 
diagnosis of breast masses which has been identified as a critical practice in diagnosing breast 
cancer.335 The triple test entails a correlation of clinical, pathologic and imaging findings. 
Regarding pathologic diagnosis, fine needle aspiration biopsy (FNAB) has been recognized as 
the most cost-effective procedure with short turnaround time,336 although core needle biopsy 
and standard surgical biopsy might be used. However, the choice among these three is 
influenced by availability of the tools and expertise in a limited-resource setting.335, 336  
   In addition to diagnosis, staging of breast cancer, to determine the extent of a disease 
is necessary for proper breast cancer management as well as providing useful information 
about the current status of cancer detection and management, and the success of breast health 
programs.35 The TNM classification of breast cancer is widely used and has been 
recommended by a number of regulatory bodies including the UICC among others.35, 295 
Unfortunately, in limited-resource countries, breast cancer is commonly diagnosed at late 
stages19, 282, 337 and is therefore characterized by high mortality.338 Therefore, breast cancer 
staging in such countries could provide revealing epidemiological information about 
opportunities for initiating or improving breast health care programs.35, 339       
  55
Regarding treatment of breast cancer, conservative surgery is currently being 
promoted.294 According to the St Gallen conference in 2009,292 the use of surgical procedures 
developed to allow a wide excision with satisfactory results (oncoplastic surgery) were 
considered standard. The sentinel node biopsy was identified as standard of care for patients 
with clinically negative axilla; axillary node dissection could be avoided in all patients with a 
negative sentinel node, and in selected patients with micrometastasis in the sentinel node. 
However, the definition of adequate surgical margin remains controversial292 and no detailed 
specific recommendation on this matter was given.292  
Other treatment modalities for breast cancer include use of radiation therapy, 
endocrine therapy, anti-HER2 therapy and the cytotoxic chemotherapy.280, 292, 340 The St 
Gallen conference 2009 recommended radiation therapy after local excision of ductal 
carcinoma in situ (DCIS) as standard292 and postmastectomy radiation in invasive cancer, for 
women with four or more axillary lymph node involved. It could also be used in particularly 
young patients with one to three nodes and in those with poor prognostic features.292 
Generally, it should be avoided in elderly patients and those with low-grade DCIS and clearly 
negative margins.292 In addition, the recommendations of the American Society for Clinical 
Oncology or the European Society of Mastology may be used to guide radiation treatment 
choice.335  
For endocrine therapy, anti-HER2 therapy and the cytotoxic chemotherapy, the St 
Gallen 2009 conference gave a detailed algorithm for the thresholds for these treatment 
modalities, although adherence to the therapeutic guidelines is greatly affected by the 
resources available in various geographic settings.292 Briefly, it recommended endocrine 
therapy for all patients whose tumors show any presence of ER, anti-HER2 therapy for 
patients with HER2 positive disease,341 and chemotherapy for patients receiving anti-HER2 
therapy and as the mainstay of adjuvant treatment of most patients with triple negative 
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tumors. However, the threshold for use of cytotoxic chemotherapy for some tumor groups was 
recognized as the most difficult to define.292 
Briefly, the Breast Cancer Guidelines for Uganda342 recommended breast self-
examination as a way of early detection, the triple assessment approach for diagnosis, the 
TNM classification for staging and surgery as the mainstay of treatment for breast cancer 
except in metastatic disease. Also, tumor-free margin should not be less than 10 mm “at 
surgery”, adjuvant radiation therapy after surgery for most patients groups and adjuvant 
systemic treatment (chemotherapy and hormonal) for all patients in Uganda, with few 
exceptions (DCIS, lobular carcinoma in situ (LCIS) and Paget’s disease) were recommended. 
Hormonal therapy alone was recommended for LCIS. Neoadjuvant chemotherapy could be 
given to down-stage the tumor before local treatment is offered.342                            
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BACKGROUND AND AIMS OF THE STUDY  
Background 
Over the years, numerous biomarkers have been proposed as putative prognostic and 
predictive factors in breast cancer that might help to stratify patients to various treatment 
regimens and targeted therapies.42, 272, 275, 305 Previous reports have described the prognostic 
biomarker profiles of breast cancer in African and African-American women,119, 282, 343 and 
striking similarities in breast cancer biology between the two groups have been reported.281 In 
Uganda, there is a paucity of reports about prognostic and molecular biomarkers in breast 
cancer, whereas a previous study analyzed HER2 oncoprotein expression in breast cancer.344 
In this population, where the incidence of breast cancer is increasing, early diagnosis remains 
a challenge and the clinical outcome continues to be poor.19  
Consequently, in 2000, the Uganda Breast Cancer Working Group launched Breast 
Cancer Guidelines for the management of breast cancer.345 Its goal was to improve the quality 
of life of breast cancer patients and their families. Specifically, it aimed at standardizing and 
harmonizing diagnosis and treatment of breast cancer. In addition, one aim was to enable 
early detection of the disease with an ultimate goal of improving survival of the patients. The 
success of such a program needs to be augmented by studies specifically designed to elucidate 
the nature, behavior, basic processes and prognosis of breast cancer in this setting. Further, 
there was a need for a study to identify significant clinico-pathological parameters that might 
assist to achieve some of the objectives of the guidelines.  
  58
Aims of the study 
 
General aim 
On this background, the aim of this study was to explore the molecular markers in 
breast cancer with special focus on molecular subtypes, angiogenesis and stem cells in an 
African population.  
 
Specific aims  
Accordingly, the specific aims of the study included:  
 
1. To explore the expression of selected basal-like markers in a series of breast cancers 
from native Ugandan women in the Kyadondo County, and to determine their 
frequency and relationship to other prognostic indicators. 
2. To evaluate the expression of EGFR and c-kit in relation to the basal-like phenotype 
and other prognostic factors in breast cancers from an African population. 
3. To explore the expression of candidate stem cell markers ALDH1 and BMI-1 in breast 
cancers from an African population and their associations with the basal-like 
phenotype (BLP) and other molecular markers. 
4. To explore tumor-associated angiogenesis in relation to the basal-like phenotype, the 
triple negative phenotype and other tumor characteristics in an African population as 
well as a non-African population. 
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MATERIALS AND METHODS  
STUDY SITES AND STUDY POPULATIONS   
This study was carried out as part of the collaboration between the Department of 
Pathology at Makerere University College of Health Sciences (MUCHS) in Uganda and 
Section for Pathology, The Gade Institute, University of Bergen in Norway. Data collection 
was done at Makerere University while laboratory analysis and writing were done at The 
Gade Institute. The Department of Pathology at MUCHS is a research and teaching centre, for 
both undergraduate and postgraduate (average 2; range 1-5 per year) students. In addition, it 
offers histopathologic diagnostic services for the national referral hospital and the other main 
hospitals from all over the country which had an estimated population of about 32,4 million in 
2009 (Figure 14).346  
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Figure 14: The population of Uganda by age group as of 2009 
 
Furthermore, it also houses the Kampala Cancer Registry (KCR), a population-based 
registry that was established in 1951 with an aim of determining incidence of cancers in the 
population of Kyadondo County.13 The Registry covers an area of about 1914 km2, which 
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comprises of Kampala, the capital city of Uganda, and the neighboring urban and semi-urban 
areas,18 with an estimated population of 1.7 million (2002);347 the female population above 15 
years old is about 530,000.  The annual incidence of breast cancer is 22/100,000 in this 
population.13 The Baganda are the largest ethnic group in the county, but all the other ethnic 
groups are represented. Analysis of the breast cancer cases recorded at the Department of 
Pathology from 1990-2000 showed that cases from Kyadondo County contributed about 28% 
of the histologically confirmed breast cancers in females in Uganda. No significant 
differences were observed in distributions of female breast cancer patients by ethnic groups 
represented by regions as well as the age structure of cancer patients from Kyadondo County 
(mean age = 46 years) and those from other counties (mean age = 46 years) (P = 0.697).   
The region is served with one 900 bed national referral hospital with attached 
oncology and radiotherapy units plus three other 100-bed missionary hospitals and hospice. 
Mammography is available at the national referral hospital but is limited to diagnostic 
purposes, and no routine screening is available.342 The study population mainly included 
female patients with breast cancer who were registered at the Kampala Cancer Registry or 
presented at the three missionary hospitals in Kyadondo County. The registry methods of 
collecting data and results have been previously described.348 A small number of study cases 
were drawn from the general population (39/192) (Figure 15).  
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Figure 15: The distribution of the study population in Uganda   
 
In addition to the above population, a second study population included female 
Ashkenazi Jewish women in North America with breast cancer who were registered in the 
medical records at the Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, 
Canada.    
 
PATIENT SERIES AND TISSUES  
Series 1 
This was the Series on which Paper I and Paper II were based. Cases of female 
patients with histologically confirmed breast carcinoma were consecutively compiled from 
the records of the Kampala Cancer Registry. Altogether, 120 cases from the period 1993-2002 
were included whereby a total of 65 cases were identified from which suitable paraffin blocks 
were available and retrieved from the departmental archives and analyzed. Duplicated cases 
due to repeated biopsies and subsequent mastectomies were included only once. These blocks 
were originally obtained from mastectomy, incisional, excisional and core needle biopsy 
specimens that were submitted to the department. Twenty other cases with inadequate tissue 
available plus 35 cases which were untraceable were excluded.  
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Series 2 
This series was the basis for Paper III and part of Paper IV (referred to as Series I in 
Paper IV). Cases of female patients with histologically confirmed breast carcinoma were 
consecutively compiled from the records at the Department of Pathology in addition to cases 
registered at the Kampala Cancer Registry. Altogether, 314 cases from the period 1990-2002  
were included whereby a total of 192 cases (Table 4) with suitable retrieved paraffin blocks 
were eventually identified. Altogether, 122 (39%) other cases were excluded. These included 
cases with inadequate tissue available; 24 metastases, 11 ductal carcinoma in situ, 7 benign, 
26 with insufficient material, 1 poorly preserved sample, 18 cases where no tumor tissue was 
identified and 35 cases where the tissue blocks could not be located.  
 
Table 4: Number of cases studied per year (Series 2)  
Year  Frequency Percent 
1990 37 19.3 
1991 37 19.3 
1992 56 29.2 
1993   8 4.2 
1994   5 2.6 
1995 14 7.3 
1996   6 3.1 
1998   5 2.6 
1999   7 3.6 
2000   4 2.1 
2001   7 3.6 
2002   6 3.1 
Total 192 100 
 
 Clinical information on the included cases was obtained from the histology request 
forms. The mean age was 46.2 years (range 18-80 years) for Series 2 (n=192 cases) and 49.8 
years (range 27-89 years) for the Series 1 (n=65 cases). Duration of clinical symptoms as 
reported by a total of 127 patients at the time of presentation ranged from 0.5-108 months 
with and average of 17.1 months. The stage of the disease at the time of presentation was 
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available in only 22 patients and the majority 12 (54.5%) were in stage 4, 8 (36.4%) were in 
stage 3. Tumor size was recorded in 31 cases and average size was 5 cm (range 1-12 cm).  
The histologic type and grade of tumor were available in 181/192 (94%) and 107/192 
(56%) cases respectively, however these were not according to the recommended criteria. 
Therefore, all cases were histologically re-typed according to the World Health Organization2 
and re-graded in accordance with the Nottingham criteria.291 Nuclear grade and mitotic count 
was also recorded as separate variables according to the same criteria.  
 
Series 3   
This was part of the series on which Paper IV was based. For Paper IV, a second 
independent patient series (referred to as Series II in Paper IV) was included. Cases from the 
ethnically restricted single hospital-based retrospective cohort study as previously described 
were used in this series.65 The study was approved by the hospital’s Institutional Review 
Board. Briefly, the patients were consecutive cases of Ashkenazi Jewish women aged < 65 
years diagnosed with a primary, non-metastatic, invasive breast cancer during 1980-1995 at 
the Sir Mortimer B Davis-Jewish General Hospital, Montreal, Quebec, Canada. In total, 239 
cases were included for the analysis and 70 other cases were excluded due to unavailable or 
unsuitable material, repeated unsatisfactory staining, or inability to amplify DNA after several 
attempts. Among the 239 cases, 24 BRCA1 and 6 BRCA2 mutation carriers were included. All 
cases were re-examined histologically and typed according to World Health Organization2 
and grading was performed in accordance with the Nottingham criteria.291 In all, 181 cases 
(76%) were treated by breast conserving therapy (BCT), while 58 cases (24%) received 
mastectomy. Adjuvant chemotherapy was given to 45% of the BCT cases and to 54% of those 
treated by mastectomy.  Radiotherapy was given to 85% of the cases treated by BCT and 7% 
of those receiving mastectomy. Hormone therapy was given to 56% of hormone receptor 
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positive patients and 22% of receptor negative cases. The median follow-up time of those who 
did not die of breast cancer was 9.3 years (n=168), and there were 69 breast cancer related 
deaths during the follow-up period.  
 
TISSUE MICROARRAY  
Altogether, 192 archival tissues (Series 2) were assembled on tissue microarray 
(TMA) blocks according to Kononen et al. (1998).349 Representative tumor areas with the 
highest histologic tumor grade preferably at the periphery of the tumor were identified on 
H&E-stained slides, and tissue cylinders with a diameter of 1 mm were punched from selected 
areas of the donor blocks and mounted into the receipt paraffin blocks using a custom made 
precision instrument (Beecher Instruments, Silver Spring, MD). To account for intratumoral 
heterogeneity and to reduce the problem of drop-outs, a minimum of 3 tissue cores were 
punched from the selected areas. Five m thick sections of the resulting TMA blocks were 
made by standard technique. Serial sections were stained with antibodies as shown in Table 5. 
Also, a total of 230 cases from Series 3 were available on tissue microarray constructed as 
previously described,101 and 4 μm pre-cut slides were made available for staining with EGFR 
antibody as described.101 Of these, 223 cases with previously registered results were used for 
further analysis. 
 
IMMUNOHISTOCHEMICAL METHODS  
For series 1 and 2, immunohistochemical staining was performed on 5 μm thick 
sections of both the conventional and TMA slides.  After sections were deparaffinized in 
xylene and alcohols, heat induced epitope retrieval methods were used for all antibodies 
except EGFR where proteinase kinase pre-digestion was used. As shown in Table 4, the 
antigen retrieval time, the antibody dilution and incubation were optimized for each antibody 
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used. The staining was performed in a Dako Autostainer for all antibodies except the BMI-1 
antibody, a non-commercial monoclonal antibody that was kindly provided by Dr Arie P. Otte 
(The University of Amsterdam, The Netherlands). The main detection system was Dako 
EnVision+ enzyme labeled polymer with 3,3’-diaminobenzidine (DAB+) as chromogen. For 
BMI-1, the Catalyzed Signal Amplification II (CSA II) kit (Dako, K1497) which is a biotin-
free tyramide signal amplification system was used. Hematoxylin was used as a counter stain. 
All incubations were done at room temperature.  Cases of breast carcinoma (ER, PR CK5/6, 
P-cadherin, ALDH1 and BMI-1), colonic carcinoma (Ki-67 p53 and EGFR), prostate 
carcinoma (Factor VIII) and gastrointestinal stromal tumor (GIST) (c-kit) with known 
immunoreactivity for the respective markers were used as positive controls. Normal breast 
tissue was used as a control for p63. Replacing the primary antibody with buffer solution 
served as the negative control.   
For evaluation of microvessel density and vascular proliferation, 5 μm conventional 
sections (Paper IV: Series 2; 192 cases; Series 3; 239 cases) were used. We employed the 
dual staining procedure with Factor VIII and Ki-67 for endothelial cell proliferation.350 
Sections were incubated with a cocktail of polyclonal rabbit anti-human Factor VIII (A0082) 
and monoclonal mouse antihuman Ki-67 antigen (Table 5). A secondary goat anti-mouse 
antibody (Dako E0433) with streptavidin alkaline phosphatase (Lab Vision) and Ferangi Blue 
chromogen kit (Biocare Medical) (Series 2) or StreptABComplex/AP (Dako K0391) and Fast 
Blue (Series 3) was used for visualization of Ki-67. For, Factor VIII staining, visualization 
was achieved by using EnVision+ and AEC+ (3-amino-9-ethylcarbazole) in both series. No 
contrast staining was applied in this protocol. 
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Table 5: Immunohistochemical staining protocols used in the present study 
Antibody Provider  Dilution Antigen 
Retrieval  
Incubation 
(minutes)  
Detection 
system 
ER Dako/1D5 1:50 MW: 15 min in TE9 buffer  30  EnVision  
PR Dako/ PgR 636 1:150 MW: 15 min in TE9 buffer  30 EnVision  
HER2 Dako/ Polyclonal 1:500 MW: 15 min 
in TE9 buffer  
60 EnVision  
CK5/6 Dako/D5/16B4 1:200 MW: 15 min 
in TE9 buffer  
30 EnVision  
P-cadherin BD/56  1:400 MW: 15 min 
in TE9 buffer  
60 EnVision  
Ki-67/MIB-1 Dako/ MIB-1 1:50 MW: 30 min 
in TE9 buffer  
60 EnVision  
EGFR Zymed/31G7 1:30 Proteinase K 30 EnVision  
c-kit Dako/ Polyclonal 1:200 MW: 15 min 
in TE9 buffer  
30 EnVision  
p63 Dako/4A4 1:300 MW: 15 min 
in TE9 buffer  
30 EnVision  
p53 Dako/DO-7 1:1000 MW: 15 min 
in TE9 buffer  
60 EnVision  
BMI-1 Dr Otte/6C9 1:1 MW: 25 min 
in TE9 buffer  
 60 CSA-kit 
ALDH1 BD/44 1:250 MW: Citrate 
buffer pH 6  
60 EnVision  
Factor VIII 
and Ki-67 
(Series 2) 
Dako/ 
Polyclonal and 
MIB-1 
1:800 
and  
1:50 
MW: 30 min 
in TE9 buffer  
60 EnVision 
and  
AP/HRP 
Factor VIII 
and Ki-67 
(Series 3) 
Dako/ 
Polyclonal and 
MIB-1 
1:400 
and 
1:200 
MW: 20 min 
in TE9 buffer 
60  EnVision 
and  
AP/HRP 
BD=BD Transduction, MW=microwave, TE9=Tri EDTA buffer pH=9, AP=Alkaline 
phosphatase, HRP=Horseradish peroxidase  
 
Evaluation of staining  
In Series 2, tumors (2.6%-4.7%) without interpretable cores because of insufficient 
tumor tissue were omitted from the analysis. In total, 183-187 could be evaluated for the 
various markers (Table 6). For all biomarkers, evaluation was done by qualitative and 
quantitative visual assessment, and criteria for evaluation is given in Table 6. For ALDH1, 
nuclear staining alone was considered non specific and was not included in the analysis. 
Tumors with any mild to strong staining in at least 10% of cells were considered as positive 
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staining for ER, PR and c-kit. Regarding EGFR, tumors with weak to strong cell membrane 
staining, whether complete or incomplete, and observed in more than 1% of the tumor cells 
were considered positive in accordance to the Dako criteria.101, 351   
 
Staining index  
To evaluate p53, p63, CK 5/6, P-cadherin, ALDH1 and BMI-1 expressions, a staining 
index (SI) (values=0-9) was determined by multiplying the score for intensity of staining 
(none=0, weak=1, moderate=2, and strong=3) with the score for proportion of 
immunoreactive cells (<10%=1, 10%-50%=2, >50%=3).65, 246, 252, 352, 353 Cut-off points for the 
various markers, determined based on median or upper quartile SI for Series 2 in 
consideration of the frequency distribution curve, the size of the subgroups and the number of 
events in each subgroup are shown in Table 6.  
 
Evaluation of Ki-67 expression  
Ki-67 proliferative rate was determined as a proportion (%) of positively stained 
tumor cell nuclei out of 500 tumor cells examined at high power (x400) using an eyepiece 
grid. In total, 7 cases with fewer than 500 cells were counted (small tumors).  The cut-off 
point for high tumor cell proliferation by Ki-67 expression was set at 15.4% (Series 1) and 
20.0% (Series 2) based on the median values (Table 6).  
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Table 6: Evaluation criteria and cut-off points for the biomarkers in the present study 
Marker  Interpretable 
cores  
Staining pattern Cut-off point  Positivity 
rate (%) 
ER  187 Nuclear  10% positive 39 
PR 187 Nuclear 10% positive 28 
HER2 187 Cell membrane  HercepTest 
criteria354 
17 
Ki-67 189 Nuclear Median;  
	 15.4%* or  	 
20.0%** =high  
51 
p53 187 Nuclear upper quartile 
>4 = positive353 
29 
Cytokeratin 5/6 186 Cell membrane 
and cytoplasm 
Median;  
1-9 = positive 
15 
P-cadherin 187 Cell membrane 
and cytoplasm 
Median;  
>3 = positive 
27 
EGFR 185 Cell membrane >1% stained 
=positive  
(Dako criteria) 
20 
c-kit 186 Cytoplasm 
and/or cell 
membrane  
10% positivity355 4 
p63 187 Nuclear Median;  
2-9= positive 
17 
ALDH1 183 Cytoplasm  Median;  
3-9 = positive 
48 
BMI-1 186 Nuclear Median; 1-9 = 
positive 
25 
 
 
Regarding Series 3, detailed information about staining methods of the various 
markers (ER, PR, HER2, p53 CK5/6, P-cadherin, and EGFR) and evaluation of the markers 
was available from previous publications.65, 101, 246, 356, 357 For EGFR, a total of 201 were 
evaluated for the EGFR staining in accordance to the Dako criteria (EGFR-DA)351 as 
previously described;101 22 tumors (9.9%) with uninterpretable cores on TMA were omitted.  
 
Evaluation of Microvessel Density (MVD) 
The average microvessel density (MVD) in a selected tumor area was assessed in 
accordance to previous studies.319, 350, 358, 359 Sections were first scanned at low magnifications 
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(x50 and x100) to identify the most vascularized area (hot spot) of the tumor. Then 10 
consecutive high power fields at x250 (field size: Series 2; 0.45 mm2, Series 3; 0.42 mm2) 
from the hot spot were examined, except in a few cases with small tumors where less than 10 
fields were examined in Series 2 (n=18). All positively stained vessels (red) were counted 
including vessels without microlumina according to Weidner’s approach,319 and clusters of 
endothelial red cells that were clearly separate from the adjacent microvessels were also 
counted. In cases with vascular nests (glomeruloid proliferations) or long winding vessels and 
branching vessels, individual lumina or segments were counted to account for increased 
angiogenic response. When no clear hot spot was identified, vessels were counted in the most 
cellular area of the tumor periphery. Areas close to necrosis were excluded in the counting. In 
Series 2, 11 (5.7%) poorly stained (weak staining or excessive background staining) tissues 
and 4 (2%) cases with insufficient tumor tissue were excluded leaving 177 cases for analysis, 
whereas 239 cases were fit for analysis in Series 3. The MVD was then determined as the 
average number of microvessels counted in the 10 fields expressed as microvessels per mm2.  
 
Vascular proliferation  
Similarly, within the same fields as used for the MVD, the number of microvessels 
containing positive proliferating endothelial cells were counted. The dividing endothelial cells 
were recognized by showing distinct Factor VIII/Ki-67 co-expression; red cells with blue 
nuclei (Figure 16). Positive nuclei outside the endothelial cell layer or within the vessel lumen 
were not counted. The average number of vessels with proliferating endothelial cells per mm2 
(pMVD) was determined and the Vascular Proliferation Index (VPI) was determined as the 
ratio of pMVD (mm2) to the MVD (mm2) given as a percentage.  
The cut-off points for high MVD, high pMVD and high VPI were determined as 
80.4/mm2, 1.7/mm2 and 3.1% for Series 2 and as 92.3/mm2, 1.9/mm2 and 3.3% for Series 3, 
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respectively based on the upper quartile values for the particular series. Thus, tumors that had 
a pMVD 	 1.7/mm2 (Series 2) or 	 1.9/mm2 (Series 3) were considered to have a high pMVD, 
and those with VPI 	 3.1% (Series 2) or 	 3.3% (Series 3) were considered to have a high 
VPI. . 
 
Figure 16: Microvessel containing positive proliferating endothelial cells as seen on dual 
staining x400. The dividing endothelial cells are recognized by distinct Factor VIII/Ki-67 
co-expression; red cells with blue nuclei were counted at x250 HPF in 10 consecutive fields 
in a selected hot spot   
 
 
Molecular phenotype sub-classification 
There is no consensus on how to define different molecular subtypes of breast cancer 
by immunohistochemical markers,233 and overlapping categories exist. We used criteria based 
on current literature231, 244, 267 for sub-classification into molecular subtypes. In accordance 
with Carey et al. (2006),231 we defined the luminal A (ER+ and/or PR+, HER2), luminal B 
(ER+ and/or PR+, HER2+), HER2+ subtype (ER, PR, HER2+) and the basal-like subtype 
(ER, PR, HER2, CK 5/6+ and/or EGFR+) subgroups (Table 7). Tumors negative for all 
the 5 markers (ER, PR, HER2, CK 5/6 and EGFR) were considered as unclassified. This 
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definition for luminal B tumors does not identify all luminal B tumors because only 30% to 
50% are HER2+ and the rest are classified with the luminal A. We therefore merged luminal 
A and luminal B into the luminal subtype. Further, in accordance with our previous studies, 
we included P-cadherin staining in some of the definitions of the basal-like phenotype.246, 252  
By using the Arnes et al. (2008)204 criteria, we defined the BLP profiles (Table 7) as 
follows: BLP1: concurrent ER, HER2 and CK 5/6+; BLP2: concurrent ER, HER2 and 
P-cadherin+; BLP3: concurrent ER, HER2 and EGFR+; BLP4: concurrent ER, HER2 
and CK 5/6+ and/or EGFR+; BLP5: concurrent ER, HER2 and positivity for one or more 
basal markers (CK 5/6, P-cadherin and EGFR). BLP4 is identical to the core basal phenotype 
(CBP) as defined by Nielsen et al. (2004)232 and Tischkowitz et al. (2007).360  
Regarding Papers I and II, tumors that expressed CK 5/6 and/or P-cadherin were 
considered to have a basal-like phenotype (BLP) in accordance to previous studies.246, 252    
     
Table 7: Criteria for molecular subgroup classification of breast cancer and basal-like 
phenotypic definitions as used in this study  
Subgroup Biomarker-criteria  
Subtype 
     Luminal A  
     Luminal  B  
     HER2 subtype 
     Basal-like subtype  
     Unclassified  
 
ER+/and/or PR+/HER 
ER+/and/or PR+/HER+ 
ER/PR/HER+ 
ER/PR/HER/CK5/6+ and/or EGFR+ 
ER/PR/HER/CK5/6/EGFR 
Basal-like phenotype  profiles  
     BLP1  
     BLP2  
     BLP3 
     BLP4  
     BLP5 
 
ER/HER/CK5/6+ 
ER/HER/P-cadherin+ 
ER/HER/EGFR+ 
ER/HER/CK5/6+ and/or EGFR+ 
ER/HER/CK5/6+ and/or P-cadherin+ and/or EGFR+
 
 
ETHICAL CONSIDERATIONS 
This study was approved by the Institutional Review Board at Makerere University 
College of Health Sciences.  
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STATISTICAL METHODS  
Statistical analysis was performed using the SPSS 15.0 statistical package. We used 
the t-test or Mann-Whitney U test to compare continuous variables between different groups. 
We evaluated associations between categorical variables using the Pearson’s 
2 test or 
Fisher’s exact test. Differences between variables were considered statistically significant 
when the p-value for any statistical test used was <0.05.  
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MAIN FINDINGS  
In Paper I, we found that the basal-like markers were expressed in 34% of the series 
of breast cancer from an African population, and they were significantly associated with 
features of aggressive tumors including high histologic grade, high nuclear grade, high mitotic 
count, and ER/PR negativity.  
In Paper II, we focused on the expression of tyrosine kinase growth factors (EGFR 
and c-kit) in relation to basal-like breast carcinoma. We found a strong and significant 
association between EGFR and/or c-kit expression and the basal-like phenotype. In addition, 
EGFR and/or c-kit expression was significantly associated with poor prognostic features; 
histologic grade, nuclear grade, mitotic count, and ER/PR/HER2 (triple negativity).    
In Paper III, we explored the expression of candidate breast cancer stem cell markers, 
ALDH1 and BMI-1 and their associations with the basal-like phenotype and other molecular 
characteristics. We found a high prevalence of ALDH1 expression in the series of breast 
carcinoma from an African population as well as a more extensive ALDH1 staining in cases 
that were positive, compared to Caucasian and Asian populations from the literature. 
Expression of ALDH1 was significantly associated with the basal-like phenotype and basal 
markers as well as features of aggressive tumors (high histologic and nuclear grades, high 
mitotic count, ER/PR negativity and p53 expression). On the other hand, BMI-1 expression 
was associated with good prognostic features, low histologic grade and ER positivity whereas 
it was inversely associated with ALDH1 staining.  
In Paper IV, we determined vascular proliferation as a marker of tumor angiogenesis, 
and found that the basal-like subtype had increased tumor vascular proliferation compared to 
the luminal subtype in two independent breast cancer series. Also, we found that increased 
angiogenesis was associated with TNP, EGFR, p53 and p63 expression.    
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DISCUSSION     
METHODOLOGICAL CONSIDERATIONS  
Patient series  
Series 1 and 2 
This was a retrospective study with some limitations. The quality of data obtained 
depends on the accuracy of the records at the Kampala Cancer Registry. The registry methods 
of collecting data and results have been previously described.348 However, completeness and 
accuracy of data in studies done by cancer registries is of major concern particularly in 
Africa.18  
Nevertheless, the Kampala Cancer Registry as a population-based registry was 
established in 1951 with an aim of determining the incidence of cancers in the population of 
Kyadondo County,13 and it is one of the longest standing cancer registries in the African 
continent.18 Some of the cases included in Series 1 as was well as Series 2 were part of the 
174 breast cancer patients enrolled for the survival study at the KCR,18 which included 
incident cases diagnosed and registered between 1993-1997. Of these, 109 cases (63%) were 
histologically or cytologically confirmed breast cancers. However, as indicated by Gondos et 
al. (2005),18 collection of follow-up data was particularly challenging, and a large number of 
patients could not be included in their study. For our study, reduced availability of archival 
tissue presented another limitation since a number of eligible cases were not evaluated; the 35 
tissue blocks on record for the year 1997 were not available.  
We eventually identified histologically confirmed breast carcinoma cases and were 
able to include 65 of 120 cases in Series 1 (1993-2002) whereas 192 of 314 cases were 
included for Series 2 (1990-2002) upon incorporating cases recorded at the departmental 
records. Altogether, 122 cases including the 35 tissue blocks on record for the year 1997 were 
not available and were not analyzed. Therefore, the unavailability of some archival tissues 
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could cause a selection bias. In addition, 31% (87 of 279) of the retrieved samples were not 
analyzed due to inappropriate tumor tissue.  
A majority of samples used in Series 1 and 2 were from patients who presented to the 
national referral hospital, and this might also represent a selection bias. However, analysis of 
the records from 1990-2000 at the department revealed that the patients from Kyadondo 
County contributed about 28% of the breast cancer patients in the whole country. Therefore, 
our results might be an indication of the general population. In addition, analysis of breast 
cancer patients from the population of Kyadondo County compared with patients from the 
other counties revealed no significant difference in the age at diagnosis.   
 
Series 3 
This series is a single hospital and retrospective cohort series from a major teaching 
clinic in Montreal, Canada. The main objective in recruiting patients was to study the impact 
of BRCA-mutations on breast cancer. Given that the frequency of BRCA-mutations are rare in 
the general population, a restricted population was considered with regard to the feasibility of 
conducting large-scale genetic analysis as well as the clinical impact of the study. Ashkenazi 
Jewish women in North America have a well-known high frequency of BRCA-mutations, and 
these can be attributed to a few dominant founder-mutations, highly simplifying the detection 
of mutations. For that reason, the study recruited only Ashkenazi women with an age 
restriction of <65 years based on the observation that breast cancers in older Ashkenazi 
women had similar frequency of BRCA-mutations as the general population.  
The study originally included 309 patients, of which 17 patients (5.5%) were 
immediately excluded due to the inability to locate tissue blocks, lack of invasive carcinoma 
in the available blocks or repeated inability to amplify DNA for mutation analysis, leaving 
292 cases. Eventually, a total of 239 cases where available after excluding 4 cases that lacked 
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follow-up information in our data base and another 49 which lacked tissue blocks or had 
inadequate staining. Of these 230 cases were available on TMA blocks. Although this 
reduction in numbers may be considerable compared to the original series we consider the 
available cases as a random selection. No significant differences in the means of the included 
cases and the complete series were detected concerning tumor size, histologic grade, axillary 
nodal status or patient age at diagnosis (data not shown).     
 
Clinical-pathological variables  
We obtained much of the clinical information by carefully evaluating the histology 
request forms. The Department of Pathology at MUCHS has a vast number of archival tissue 
as well as accompanying histology request forms and reports.  In collaboration with Centre 
for Disease Control and Prevention (CDC), all records available at the department up to 2000 
were computerized. This made it easy to identify duplicate cases as well as identify more 
cases for Series 2 in comparison with the records at the KCR.  
However, relative lack of clinical information was a limitation of this study.   Accurate 
information about prognostic variables like tumor size was available in only a few cases 
(31/192; 16%), while the stage of the disease at time of diagnosis was also available in a 
limited number of cases (22/192; 12%). In addition, lack of outcome or follow-up information 
for most of the patients on record caused limitations in assessing the actual prognostic 
significance of the studied variables.  
 
Use of archival tissue  
The main advantage in using archival tissue for research lies in the availability of large 
tissue archives in pathology laboratories as well as long follow-up of a large patient series. 
This presents an invaluable tool for research and it has been demonstrated that most proteins 
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retain their antigenicity for more than 60 years.361 This study is based on material from the 
University teaching hospital in Uganda and a major Canadian research clinic originating from 
1980. However, variations in tissue handling including fixation time and methods, sampling 
techniques and storage conditions are some of the major disadvantages as these would reduce 
immunoreactivity of some antigens.362, 363 The large archival repositories have been 
supplemented by the use of tissue microarray.  
 
Tissue microarray (TMA)  
The use of tissue microarrays is an efficient approach in studies of most biomarkers 
and significantly reduces costs and time as well as conserving research tissues has facilitated 
the use of large archives. The tissue microarray technique has been validated in several 
studies361, 364, 365 since its introduction in 1998349 and has been well established in our research 
group at The Gade Institute since 2000. After a few practice sessions, precision and accuracy 
was achieved and we used this technique to assemble the 192 cases (Series 2) for analysis. 
Similarly, 230 cases from Series 3 were assembled and made available to our group for 
staining. However, regarding evaluation of angiogenesis (Paper IV), conventional 5 μm thick 
tissue sections were used as well as in Paper I and II with 65 cases.   
Further, we used pre-cut sections for both conventional slides and the TMA slides 
which were stored at 20o C, and recent studies have indicated that stored slides can still be 
valuable for research purposes in spite of the aging effects.366  
    
Use of immunohistochemical methods  
Immunohistochemistry is widely used to study expression of specific proteins in 
human malignancies and is an invaluable tool in assessing prognostic and predicative 
biomarkers in breast cancer.367 Although formalin fixation retains tissue morphology, antigens 
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may be masked or even lost during fixation. Thus, the fixed form of proteins must be 
adequately retrieved to be recognized by antibodies. Antigen retrieval is one of the most 
important factors for achieving accurate and consistent results for biomarker studies by IHC. 
Consequently, different methods of antigen retrieval have evolved as an approach to 
standardize immunohistochemistry protocols for formalin fixed archival tissue, with 
enzymatic digestion and heat-induced retrieval being the best described.368 The requirements 
for optimal staining results vary with the choice of antibody as well as the antigen of interest, 
in terms of the pH of retrieval buffer, the heating time and the temperature. We used a test 
battery approach in staining some of the study cases as well as control tissues including 
different retrieval buffers with different boiling schemes, different antibody dilutions and 
different incubation periods.  
 However, antigen retrieval of the archival tissue presented one of the biggest 
challenges of this study. Whereas prolonged formalin fixation is rarely a problem in some 
institutes,369 it might be a major concern at our department at MUCHS. There is a 
considerable variation in the fixation times in formalin at our department (MUCHS) which 
might induce a bias towards prolonged fixation considering the years that were included. 
Moreover, the actual fixation time is difficult to determine. Studies have shown that 
prolonged formalin fixation might lead to decreased antigenicity of some antigens.362, 363 
These factors might have contributed to the difficulty in antigen retrieval, although, this was 
overcome by determining the appropriate antigen retrieval times for each antibody under 
consideration362 as described above.   
The choice of antibody clones used was done in consideration of the current literature 
for the particular antigen in question and considering widely used antibodies. We generally 
preferred antibodies that had been previously used by our group for consistency and adjusted 
for differences in reactivity between various tissues by modifying the staining protocols. 
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Accordingly, for the simultaneous dual staining we used Factor VIII which has been used in 
breast cancer and other cancers by multiple studies in our laboratory (The Gade Institute) with 
good results and is now well established,254, 350, 370-372 although CD31 and CD34 has been 
considered to be good alternatives.373 Previous reports have also shown that the staining 
results using the three antibodies (Factor VIII, CD31 and CD34) are comparable.374 In 
addition to these three widely used pan-endothelial cell marker, another antibody CD105 has 
been used in breast cancer and other tumors.375-378 CD105 is reported as a highly a specific 
marker for endothelial cells and has been shown to bind only to activated endothelial cell,375, 
378 and may be better marker of angiogenesis in tumors378-380 although a number of studies in 
breast cancer  have mainly used fresh or frozen tissue.375, 378, 381 Also, the non-commercial 
BMI-1 antibody (donated by Dr Arie Otte, The University of Amsterdam, The Netherlands) 
used in this study, has been used in various previous studies and was validated in our 
laboratory;382 Western blot analysis supported specificity and correlations with the 
commercial BMI-1 antibody. For candidate antibodies, the supplied data sheets from the 
manufacturers and literature studies provided information on their reactivities and were tested 
accordingly before the main staining.  
Appropriate positive controls were selected from well-known sections that expressed 
the antigen of interest and were included for every round of staining. Negative control was 
achieved by omitting the primary antibody.  
  Regarding the detection method, whenever possible we used the EnVision system 
which on top of reducing the cost of staining, reduces the assay time and the workload.383 
Also, we employed the Dako Autostainer which ensures equal staining conditions for all 
samples in every run, for all antibodies except the BMI-1 antibody.  
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Evaluation of staining: staining index  
We employed the staining index (SI) (values=0-9) as the method of assessing 
immunohistochemical staining for most markers in the study. This is a semi-quantitative and 
subjective grading system which considers both the intensity of staining and proportion of 
cells stained, obtained as described in the methods section.  This method of evaluation is now 
a well established robust and reproducible parameter and has been validated by several studies 
carried out in our team at The Gade Institute.252, 382, 384-387  
 Selection of cut-off points used to create dichotomous variables was based mainly on 
median values and quartiles of the staining index, considering the frequency distribution 
curve, the size of the subgroups and the number of events in each subgroup. A selected cut-off 
point, once chosen, was then used consistently in all analyses involving that marker.  
   
Estimation of microvessel density  
Angiogenic activity is heterogeneous within a given tumor, and MVD assessment 
within the most vascularized selected tumor area (hot spot) has been the most widely used 
technique to quantify intratumoral angiogenesis in breast cancer, since its introduction in 
1991.319, 321 The major drawback, however, has been lack of standardization of the method 
used to assess MVD,321 although the method used by Weidner et al. (1991)319 has been 
generally accepted with some modifications.350, 358, 359 The variability is mainly due to issues 
like choice of antibody and “hot spot” based counts versus “global” counts as well as 
automated versus manual counts. It is now generally agreed that the vessel counts should be 
in the hot spots preferably at the tumor periphery.317 In accordance to previous studies at our 
institute, we used a double staining with Factor VIII/Ki-67 for endothelial cell 
proliferation,350, 370 and we evaluated tumor angiogenesis in hot spots counting vessels in 10 
fields at x250 magnification and eventually determined MVD per mm2. MVD estimation by 
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Weidner’s method is fairly rapid, but is influenced by the training and experience of the 
investigator. Thus, after initial discussion of the criteria and some basic training, a training set 
(n=25) was scored twice for intra-observer variability with good results (=0.83). The inter-
observer variability (HN, JBA) using the same set was also good (=0.64).        
In addition, availability of a representative tissue block359 for estimation of MVD in 
the archival tissue depends on the initial tumor sampling technique that was done by both the 
clinician and at the department since it is not uncommon for the clinicians to submit just a 
small part of the tumor of a mastectomy specimen (personal observation from Uganda). 
However, previous studies have reported a concordance rate of 71-78% between different 
blocks sampled from the same tumor;388 thus, use of archival tissue did probably not greatly 
affect the estimated microvessel count. 
 
Vascular proliferation index  
 Vascular proliferation determined by the number of  vessels with evidence of dividing 
endothelial cells given by dual immunohistochemical staining may be a better indicator of 
angiogenesis than MVD which is more of a marker for the metabolic demand of tissue rather 
than angiogenesis.138 Studies from our laboratory have shown that counting vessels with 
actively dividing endothelial cells revealed significantly stronger associations with clinico-
pathologic phenotype and patient prognosis in endometrial and prostate cancers.350, 389 In this 
present study we accordingly determined vascular proliferation as a marker of angiogenesis.   
     
  82
Molecular sub classification  
Determining the molecular subtype of breast cancer by immunohistochemical markers 
has some limitations.233 There is no consensus on how to define basal-like breast cancer and 
overlapping categories exist. Although a majority of the basal-like breast cancers are triple 
negative, ER or HER2 expression has been reported in about 15%-45% of the basal-like 
cancers.226, 232, 233 Therefore, the obvious limitation of using IHC to define subtypes is that it 
might result into misclassification bias of some tumors. In this study, we used criteria based 
on current literature.231, 244, 267 In this classification, the definition of basal-like breast cancer 
as ER/PR/HER/CK5/6+ and/or EGFR+ encompasses the criteria used by Nielsen et al. 
(2004)232 which showed a sensitivity of 76% and specificity of 100% to identify the basal-like 
phenotype as defined by expression profiling analysis. In addition, we used individual basal 
markers for this subgroup such as cytokeratin 5/6, P-cadherin and EGFR as well as composite 
definitions such as basal-like subtype, various basal-like phenotypic profiles (BLP1-5) and the 
triple negative phenotype which overlaps significantly with the basal-like category (see Figure 
12).   
 
Comparison with previous studies  
There is no uniformly accepted method for the registration of IHC staining that can be 
applied for most biomarkers. This presents a challenge in interpretation and comparison of 
results from different research groups, and this was a major source of concern according to 
the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK).390 
Hence, the report encouraged transparency and complete reporting to facilitate usefulness and 
reproducibility of scientific data in the field of tumor biomarker research.     
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DISCUSSION OF MAIN FINDINGS    
Molecular subtypes of breast cancer 
Microarray studies have indicated that breast cancers may be divided into five major 
subtypes.225, 227 Defined by IHC staining, the luminal A subtype is the most prevalent 
contributing 47-69% of all breast cancers. The other subtypes contribute 8-25% (basal-like), 
6-17% (luminal B), 6-10% (HER2 subtype) while the unclassified accounts for 1-7%.231, 241, 
244, 267 The normal breast-like subtype originally identified by gene profiling studies226 is still 
poorly characterized immunohistologically.229, 233 The basal-like and the HER2 subtypes are 
of particular interest because of their prognostic implications.226 The basal-like phenotype 
partially overlaps with the triple negative phenotype (ER/PR/HER2),360 which is another 
category of breast cancer that has attracted attention as an easily recognizable prognostic 
group with therapeutic implications.391 It contributes about 10-24% of all cases.391, 392  
Studies have reported that both the basal-like and the TNP are overrepresented in 
young African-American and African women,119, 120, 231, 393, 394 and striking similarities have 
been reported in features of breast cancer in the two groups.281 Therefore, an important aspect 
of our studies was to determine the prevalence of the basal-like phenotype and its associations 
with other tumor characteristics with focus on breast cancer in an African population.  
In agreement with these previous reports, we found a high prevalence (34%) of the 
basal-like differentiation in the series of tumors from an African population (Paper I) using 
two individual basal markers CK5/6 and P-cadherin. This is comparable to what Carey et al. 
(2006)231 found (39%) in premenopausal African-American women. Further, in Paper III, 
with more cases included, the prevalence of the basal-like subtype (22%) as defined according 
to Carey et al’s definition, using composite criteria, was again comparable to the overall 
prevalence of BLP in African-American women (26%) reported in that study. Studies in 
Caucasians have reported a prevalence of 8-16%.231, 244, 267 In the same vein, we found a 
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higher prevalence of triple negative tumors (40-41 %) (Papers II and III) compared to 
previous reports (10-21%)  among Caucasians.392, 393, 395, 396 The high frequency of both the 
BLP and TNP in patients of an African population compared to Caucasians provides further 
support that breast cancer in women of African ancestry might be, to some extent biologically 
different from that in Caucasians.282, 343, 397-399 Indeed, a recent gene expression profile study 
has indicated that differences beyond the knowledge of current markers might exist in tumor 
biology of African-American compared to Caucasians.400 Moreover, breast cancer in the black 
and African-American women occurs at a much younger age (10-15 years younger on 
average) than in Caucasians.281, 282 
However, the higher frequency (40-41%) of TNP (Papers II and IV) in our study 
compared to some studies in African-American (21-25%)393, 394, 396 might indicate that other 
factors besides ethnical and racial background are important in breast cancer, although others 
reported comparable frequency (47%).395 Further, more comparative studies are required to 
answer this. 
  
Basal-like subtype and expression of EGFR and c-kit     
We found a significant association (Paper II) between EGFR or EGFR and/or c-kit 
expression and the basal-like category232, 233, 245, 360 as well with the triple negative 
phenotype401 in accordance with other studies. This provides more support to the stipulation 
that the basal-like258 and triple negative tumors312 represent a group of breast cancers that 
might potentially benefit from EGFR-targeted therapies in addition to chemotherapy. Whether 
these tumors will actually respond to such therapies is yet to be known392, 402 from the results 
of on-going phase II clinical trials in the basal-like subtype as well as triple negative 
tumors.403, 404 Studies in cell lines have shown that basal-like cells are sensitive to EGFR 
targeted therapy in combination with chemotherapy405 and the two act synergistically. Basal-
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like cells are more sensitive to growth inhibition by dasatinib, a multi-targeted kinase 
inhibitor, compared to the luminal cell lines.264  
Moreover, we (Paper II) and others232, 244 found that 23-31% of basal-like breast 
cancers express c-kit, whereas about 50% of BLP express either EGFR or c-kit, or both 
(Paper II). However, results from phase II trials with a potent inhibitor of tyrosine kinases 
including c-kit are still negative.406   
 
Basal-like subtype and tumor-associated angiogenesis   
We found that tumor angiogenesis was increased in the basal-like tumors compared to 
the luminal subtype (Paper IV) in two independent breast cancer series. This is in agreement 
with a previous report which found that glomeruloid microvascular proliferation was 
significantly more frequent in the basal-like phenotype.253 In the present study, vascular 
proliferation was significantly associated with multiple basal markers (such as CK 5/6, P-
cadherin and EGFR). To support this, gene expression studies have indicated that the majority 
of basal-like tumors express the activated wound-response signature, which represents 
important processes associated with angiogenesis among others.238  
Anti-angiogenesis treatment has now been approved for breast cancer and other tumor 
types,407 although it is presently not clear whether this treatment should be given to certain 
subgroups of malignant tumors.160 Our findings therefore suggest that anti-angiogenic therapy 
might be a possible target in the basal-like subgroup.  Further clinical trials targeting different 
pathways will give more insight on this.160  
Similarly, the significant association between TNP and increased tumor angiogenesis 
which we found in our study (Paper IV), in accordance with previous reports,52, 320 supports 
the rational of phase II clinical trials that are currently accessing the potential benefit of triple 
negative tumors from a combination of anti-angiogenic therapy and chemotherapy.233 Current 
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studies should also address whether markers of BLP or TNP might be used to predict the 
response to anti-angiogenic therapy in breast cancer.   
 
Basal-like subtype and poor prognosis   
Basal-like breast cancer is an aggressive phenotype, but the underlying biology is still 
poorly understood.233 It has been reported to have a poor prognosis226 with a specific pattern 
of metastatic spread to sites associated with decreased survival,255 like hematogenous 
metastases.230 Several independent studies have established that angiogenesis plays a central 
role in tumor development and subsequent metastases.139, 144, 153 To speculate, increased 
angiogenesis in basal-like breast cancer might partly explain the frequent metastasis reported 
in this subgroup. In general, the prognostic significance of increased angiogenesis as 
determined by MVD has been confirmed in several independent studies.136, 316-318, 320 
Additionally, we found (Paper I) that the basal-like phenotype was associated with 
features of aggressive tumors in accordance with previous reports231, 245, 267, 408 as well as 
EGFR expression (Paper II). Given that, both EGFR expression232 and increased 
angiogenesis are associated with poor prognosis, and our findings provide further evidence 
that the basal-like breast cancer exhibit multiple features of aggressive tumors which, in part, 
explains the poor prognosis.226  
 
Cancer stem cells and the basal-like subtype   
Our results (Paper III) showed that the basal-like subtype was significantly associated 
with ALDH1 expression which has been associated with poor clinical outcome in breast 
cancer.193, 194 Also ALDH1 expression was associated with the different BLP profiles, as well 
as with individual basal markers CK 5/6, P-cadherin and EGFR (Paper III), similar to what 
others have reported.194 In breast cancer mouse models, breast cancer stem cells which 
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expressed a combined CD44+/CD24/low/ALDH1+ phenotype showed an especially high 
tumorigenic capacity.194  
Further, others have suggested that the proportion of cancer stem cells within breast 
tumors may correspond to the risk of distant metastases185, 186 and the heterogeneous 
phenotypic and molecular traits of breast cancers are a function of their CSC content.184  In 
the integrative model of breast cancer metastasis it has been proposed that oncogenic 
mutations which occur in the breast stem cells might generate ‘poor prognosis’ metastatic 
breast cancers.181 In these cancers, the resulting breast cancer stem cells under the influence of 
stromal fibroblasts have the ability to metastasize, and variants of the cancer stem cells which 
express different tissue-specific profiles determine the tissue selectivity for metastasis.181 The 
frequent hematogenous metastases as well as specific pattern of metastatic spread that have 
been reported in the basal-like subtype might relate to the significant association found 
between ALDH1 expression and the BLP. Moreover, we also found more extensive ALDH1 
staining in cases that were positive, compared to reports among Caucasians and Asians 
populations.194, 409 More studies are required to understand the biology of cancer stem cells in 
the development and clinical behavior of basal-like breast cancer.    
ALDH1 expression has been associated with resistance to chemotherapy193, 222 in 
breast cancers. Also, there is some evidence that the limitation of chemotherapy and radiation 
treatment may be associated with the inability to target breast cancer stem cells.191, 202, 328, 329, 
410 To speculate, our findings might be related to the aggressive behavior and therapy resistant 
features of the basal-like breast cancer subtype.202, 226, 410, 411     
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Cancer stem cell markers in African breast cancer     
 Our result indicate a higher prevalence of ALDH1 expression (48%) in a series of 
breast cancer from an African population  (Paper III) compared to 19% and 30% in two 
different Caucasian populations194 and 10% and 19% in Asian populations.193, 409 We also 
found more extensive staining in positive cases.194, 409 Further, in comparison with data 
derived from breast tumors in Caucasian and Asian populations193, 194, 409 regarding ALDH1 
positivity rate in tumors with similar characteristics (histologic grade, ER, HER2, Ki-67), we 
observed that tumors from our study (Paper III) stained in a higher percentage of cases in 
poor prognosis categories (such as high histologic grade, ER negative cases, and tumors with 
high Ki-67 expression). Thus, apart from methodological discrepancies, biologic differences 
might be present when comparing breast cancers from African and Caucasian populations.282, 
284, 343, 397, 398, 400 In line with this, a difference in the spectrum of tumor characteristics and 
prognostic features such as the presence of tumor necrosis, low ER positivity rate, high HER2 
positive rate, p53 expression, overexpression (p16 and cyclin E) as well as low expression 
(cyclin D) of cell-cycle regulatory proteins and a high frequency of basal-like features have 
been reported in African and African-American patients when compared with breast cancers 
among Caucasians.32, 119, 231, 282, 396, 398  To speculate, our findings might indicate that poor 
prognosis of breast cancer in Africans and African-American is a preordained event. In 
support of this, a high prevalence of TNP in young premenopausal African-American was a 
contributory factor to the poor outcome which was reported in that group,394 whereas other 
independent studies have reported poor prognosis in African and African-American 
patients.19, 281 Indeed, a poorer outcome of breast cancer has been observed in the two 
populations compared to Caucasians.282, 285, 412  
Additionally, we found that ALDH1 expression was significantly associated with 
features of poor prognosis including high histologic grade, high nuclear grade, high mitotic 
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count, p53 expression and ER/PR negativity (Paper III). Also, ALDH1 expression was 
associated with a short duration of symptoms. Moreover, we found a significant association 
between ALDH1 expression and the triple negative tumors, a group whose poor prognosis has 
been widely reported.323 Our results provide further support that ALDH1 status might be an 
indicator of poor prognosis in breast cancer.194, 409  
To support this, BMI-1 expression, a candidate stem cell marker,204 which has been 
associated with features of good prognosis such as low grade, low mitotic count, ER positivity 
and absence of TNP in breast cancer in our study and in previous reports,204, 214, 413 was 
inversely associated with ALDH1 expression (Paper III). As expected, the frequency of 
BMI-1 was lower (25%) in the series of breast cancers from an African population compared 
to breast cancer from Caucasian and Asian populations (43-62%).204, 214 Others have found 
different results, BMI-1 being associated with poor prognosis.186, 214, 414 In addition, Glinsky et 
al. (2005)186 found that the expression of a BMI-1 driven 11 gene signature was associated 
with the risk of metastases in breast carcinoma. The reason of this inverse relationship is not 
known. To speculate, given that, BMI-1 has been implicated in breast carcinogenesis and is 
involved in stem cell activation and self-renewal,210 whereas ALDH1 is reported to have a 
role in early stem cell differentiation, proliferation and survival,215-217 this might suggest a 
regulatory relationship between ALDH1 and BMI-1 during carcinogenesis. Hence more 
studies are required to understand the regulatory pathways and biology of cancer stem cells in 
breast cancer carcinogenesis.   
Finally, to speculate, the significant association between a basal-like phenotype and 
increased angiogenesis, EGFR expression or ALDH1 expression might indicate that patients 
with basal-like breast cancer may benefit from combined therapies targeting pathways 
involved in cell proliferation, angiogenesis as well as cancer stem cell activation and 
proliferation.  These hypotheses still require further exploration.      
  90
CONCLUSIONS   
1. The basal-like phenotype was frequent in the series of African breast cancer from the 
Kyadondo County in Uganda and is strongly associated with features of poor 
prognosis (Paper I).  
2. There was a high frequency of tyrosine kinase growth factor (EGFR and c-kit) 
expression in basal-like breast carcinoma in the series of breast cancer from Uganda, 
and their expression was associated with features of aggressive tumors. (Paper II). 
3. There was a high frequency of ALDH1 expression in the series of invasive breast 
carcinomas from Uganda which was significantly associated with a basal-like 
phenotype and with features of aggressive tumors (Paper III).  
4. Tumor-associated angiogenesis was increased in basal-like breast cancer in two 
independent series of breast cancer and was associated with the triple negative 
phenotype, EGFR expression, p53, p63 and with features of aggressive tumors (Paper 
IV).  
  
CONCLUDING REMARKS AND FUTURE PROSPECTS   
Breast cancer is a highly heterogeneous disease in terms of tumor biology, clinical 
behavior, prognosis and response to treatment.45 It is believed that this is due to molecular 
differences even within histologically similar tumors.178, 224, 261 Interestingly, race appears to 
be one of the contributory factors to the final outcome.9, 33, 281, 286, 399, 415-417  
In line with the aim of this study, we have explored novel molecular markers that 
could be relevant for the understanding and management of breast cancers in African patients. 
We observed that breast cancer is occurring at a young age (mean 46 years) during the most 
productive period of the women. This might have implications on the socio-economic status 
of the families affected.342  
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Additionally, we found a high frequency of poor prognosis features in the series of 
breast cancers from Ugandan women including a high prevalence of basal-like breast cancer, 
the TNP and high ALDH1 expression. These factors might influence the final clinical 
outcome of breast cancer in this population.18, 19 The prognostic significance of the high and 
extensive ALDH1 expression deserves further investigations.  
Our results have indicated another potential therapy target258 for the basal-like 
subtype, since tumor angiogenesis was found to be increased in this category. Thus, well-
controlled clinical trials of targeted therapy combining multiply pathways are urgently needed 
especially in a population where early diagnosis and effective treatment is especially 
challenging.19 However, standardization of the method used to assess tumor angiogenesis is 
still required.321 
Regarding immunohistochemistry, optimal antigen retrieval is a major concern in both 
research and the routine setting. The continuing need for routine assessment of hormonal 
receptors and HER2 to select high-risk patients and provide valuable information on treatment 
options for breast cancer patients in Uganda cannot be overemphasized. Fortunately, the 
establishment of routine IHC staining for breast cancer is under way, and personnel are 
available and have been trained. However, lack of adequate infrastructure is still a problem in 
some areas.   
 On the basis of the literature and the present study, we suggest the routine assessment 
of hormonal receptors and HER2 for treatment of breast cancer patients in African 
populations. The histologic evaluation of breast carcinoma specimens, including the fixation, 
should be standardized according to guidelines and specified in the pathology report. This will 
ensure an improved quality as a basis for better treatment. Regarding research, more clinico-
pathologic studies are required to determine the significance of specific entities such as basal-
like breast cancer and triple negative tumors in Uganda and how to best stratify patients 
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towards traditional treatment as well as novel targeted therapies. Other molecular markers in 
translational breast cancer research also need to be explored and validated in African 
populations. Ultimately, clinical studies should also be performed in this setting.  
In a country like Uganda, with limited resources, and where breast cancer incidence is 
increasing rapidly, health policies have to be designed to promote early diagnosis in order to 
improve clinical outcome. National diagnosis and treatment guidelines for breast cancer in 
line with the WHO recommendations, considering the limited resources, will help promote 
equity of health care delivery.  At the policy level, our results underscore the need to establish 
routine assessment of ER/PR and HER2 in breast cancer patients in addition to the currently 
used prognostic factors. This will improve the quality of medical care offered to patients by 
the health care system.      
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ERRATA 
Introduction: Page 46, paragraph 2, line 6: “…experienced pathologists,289, 290…” should 
read “…experienced pathologists,289, 290, 291…”.  
Page 47, paragraph 1, line 1: “…be examined.275, 291, 293…” should read “…be examined.271, 
275, 293…”, paragraph 2, line 4: “…examination.291…” should read “…examination.271…”, 
paragraph 2, line 7: “…retraction spaces.275, 291” should read “…retraction spaces.271, 275” and 
paragraph 3, line 6-7: “…categorized as pT (corresponds to T category), pN and pM 
(corresponds to M category)…” should read “…categorized as pT; primary tumor (the pT 
categories correspond to the T categories), pN; regional lymph nodes and pM; distant 
metastasis (the pM categories correspond to the M categories)…”.  
Page 55, paragraph 2, line 10: “…choice.335” should read “… choice.294” 
Materials and methods: Page 64, paragraph 3, line 4: “..Table 4..” should read “..Table 5...”. 
Discussion: Page 77, paragraph 2, line 2: “…research tissues has facilitated…” should read 
“…research tissues and has facilitated…”.  
Page 87, paragraph 2, line 11: “…BLP” should read “…BLP in our study (Paper III).”.   
Page 88, paragraph 1, line 14: “…(cyclin D) of cell-cycle regulatory proteins…” should read 
“…of cell-cycle regulatory proteins  (cyclin D)...”. 
Paper II: Page 517, Statistical methods, paragraph 1, line 3: “…G2...” should read “…
2 …”. 
Paper III: Page 370, Patient series, paragraph 1, line 3: “…Cancer Registry at the…” should 
read “…Cancer Registry and at the…” and Page 371, Molecular subtypes, paragraph 1, line 8-
9: “…(ER, HER2 and CK 5/6 and/or EGFR+)…” should read   “…(ER, PR, HER2 
and CK 5/6 and/or EGFR+)…”. 
Paper IV: Page 6, Patient series, paragraph 1, line 3: “…Cancer Registry at the… ” should 
read “…Cancer Registry and at the…” and Page 16, Discussion, paragraph 1, line 3: “…Our 
previous study...” should read “…A previous study...”. 
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